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General Introduction 
 
 
1.1 Cancer and prostate 
 
Finding a cure for cancer is a quest many life-scientists are on. Whether a cure for 
all types of cancer ever can be found, is doubtful. More probable, little pieces of 
knowledge will form a more complete view of cancer and will provide us with new 
targets for intervention. Cancer development is complex and treatment has to aim at 
inhibiting many facets of cancerous growth and spread. 
In this chapter, the complexity of prostate cancer development, at the molecular 
level, is described. Furthermore, the use of conventional and modern techniques for 
discovery of new targets for intervention is discussed. One of the potential targets 
(REPS2) and its function in cellular processes is described in more detail.  
 
1.1.1 Prostate development 
 
To describe the development of prostate cancer, I will first discuss normal 
development of the prostate. The prostate originates from the embryonic urogenital 
sinus, consisting of mesenchyme and epithelium. Interactions between mesenchyme 
(stroma in the adult prostate) and epithelium are necessary for prostate development, 
and only in the presence of androgens prostatic development occurs (Marker et al., 
2003). During development of the prostate, androgens act on androgen receptor (AR)- 
expressing mesenchymal cells. The mesenchymal cells induce epithelial duct formation 
and differentiation into secretory epithelial cells. In turn, epithelial cells stimulate 
mesenchymal cells to differentiate into smooth muscle cells. Although epithelial 
development seems to be dependent only on androgen action in the mesenchyme, AR 
expression in the epithelium is obligatory for proper secretory function in adulthood 
(Cunha et al., 2003). The indirect regulation of epithelial growth and differentiation 
suggests the presence of paracrine, androgen-induced mediators, that are secreted by 
the mesenchyme and act on epithelial cells. Likely candidates are soluble growth 
factors and many are suggested to play a role. Fibroblast growth factors, FGF7 and 
FGF10, have been implicated (Thomson, 2001), as well as epidermal growth factor 
(EGF), and transforming growth factors TGFα, TGFβ1 and TGFβ3 (Haughney et al., 
1998). During adulthood, maintenance and homeostasis of the prostate gland need to 
be controlled, and this also requires functional interactions between stroma and 
epithelium. The smooth muscle cells of the stroma maintain epithelial structure and 
function, and the epithelial cells maintain smooth muscle differentiation. Androgens are 
necessary for these interactions; if androgens are removed, the prostate regresses by 
apoptotic cell death (Isaacs et al., 1994).  
During prostate carcinogenesis, stromal-epithelial interactions become disrupted. 
This disruption could occur through loss of normal homeostatic control by genetic 
changes in epithelial or smooth muscle cells or both (Hayward et al., 1997). Abnormal 
secretion of androgen-induced or constitutively expressed factors by epithelial cells, 
abnormal stimulation of epithelial proliferation by stroma, abnormal expression of 
growth factors and growth factor receptors, and changes in the extracellular matrix, all 
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are suggested mechanisms that may contribute to carcinogenesis of the prostate 
(Cunha et al., 2003).  
 
1.1.2 Prostate cancer 
 
For the western male population, the lifetime risk to die from prostate cancer is 
estimated to be 3% (World Cancer Report 2003, WHO). As many as 33.3% of men 
over 80 are estimated to have undetected prostate cancer foci (Sanchez-Chapado et 
al., 2003). However, since prostate cancer growth is slow, most men will die from 
other causes (Ruijter et al., 1999). The major problem of prostate cancer is that 
detection of the early treatable stages is difficult and treatment of late stages is only 
palliative. Thus far, the most powerful diagnostic tool for prostate cancer is detection 
of a rising level of prostate-specific antigen (PSA) in the serum. The serum 
concentration of this protein correlates reasonably with tumour stage and volume 
(Noldus et al., 1998; Polascik et al., 1999). However, despite the widespread use of 
PSA screening, one-third of new cases has already developed locally advanced disease 
at detection (Catalona et al., 1993; Johansson et al., 1997). Initially, treatment of 
prostate cancer consists of local therapies like prostatectomy and radiation, or a 
“watchful waiting” strategy is chosen, pending stage of disease and age of the patient. 
Although about two-third of patients are cured after local therapy, in the remaining 
one-third the cancer had already spread beyond the surgical margins. These tumours 
cannot be removed and will eventually develop into advanced metastatic disease 
(Barry et al., 2001; Ward et al., 2003).  
 
Figure 1.1. Different stages of prostate cancer and the accompanying treatment options  
Treatment of prostate cancer is only curative when the cancer is restricted to the prostate or its direct 
vicinity. During progression of prostate cancer towards metastatic disease (spread mainly to the bone), 
dependence on androgens for growth decreases and treatment options become limited. 
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Patients with metastatic prostate cancer receive androgen ablation therapy, which 
is based on the dependence of prostate cells on androgens for growth and survival. In 
80% of cases, androgen ablation reduces tumour size initially, but a portion of the 
tumour, consisting of androgen-independent cells, remains (Goodin et al., 2002). 
These androgen-independent cells are thought to originate from androgen-sensitive 
cells that undergo adaptation, or are intrinsically present and selected for during 
androgen ablation (Patterson et al., 2002). Either way, the importance of biochemical 
and molecular mechanisms involved in appearance of androgen-independent cells 
during prostate cancer progression is generally recognised and will be discussed 
further. 
 
1.2 Androgen and growth factor signalling 
 
Androgen-induced growth and survival is required for proliferation and maintenance 
of human prostate cells. Prostate cancer development into the advanced stages at 
some point usually involves a transition from androgen-dependent to androgen-
independent growth, and consequently these cells then use other signalling pathways 
for proliferation and survival. These alternative pathways may still involve androgen 
receptor signalling or are truly androgen receptor-independent.  
 
1.2.1 Androgen signalling cascade 
 
Androgens are necessary for development, maintenance and functional 
differentiation of the prostate (Arnold and Isaacs, 2002; Cunha et al., 1987). 
Androgens bind to the androgen receptor (AR), an intracellular receptor that becomes 
activated upon ligand-binding. After androgen binding the receptor undergoes 
conformational changes, leading to dimerization and translocation to the nucleus. The 
activated nuclear AR can bind to specific sequences in promoter regions of androgen-
regulated genes and modulate transcription (Balk, 2002; Gelmann, 2002). Regulation 
of androgen-induced or -repressed genes involves recruitment of several co-activators, 
co-repressors, transcriptions factors, and other nuclear proteins (Brinkmann et al., 
1999). Androgen-regulated genes are involved in many cellular processes in the 
prostate: cell cycle control, DNA repair, lipid metabolism, signal transduction, and 
more (DePrimo et al., 2002). 
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Figure 1.2. AR activation and transcription modulation 
The AR is activated when ligand enters the cell and binds the receptor. A conformational change 
dissociates the androgen receptor from its accompanying chaperone proteins. The receptor becomes 
phosphorylated, homo-dimerizes and translocates to the nucleus. In the nucleus, the receptor modulates 
transcription after recruitment of several co-activators, co-repressors, transcription factors and other DNA 
modifying proteins. 
 
 
 
1.2.2 AR involvement in prostate cancer 
 
There are two important questions with respect to androgen signalling and 
carcinogenesis of the prostate: 
 What is the role of the AR in development and progression of prostate cancer? 
 Does androgen ablation therapy contribute to development of androgen-
independent prostate cancer?  
AR signalling has been target for treatment of advanced prostate cancer since 
Huggins and Hodges (1941) found that prostate cancer regresses when androgens are 
removed from the circulation by surgical removal of the main source of androgen, the 
testes (Huggins and Hodges, 2002). Blocking the AR signalling cascade leads to 
induction of apoptosis in the prostate and consequently regression of the tumour 
(Kyprianou et al., 1990). Although 80% of patients respond to androgen ablation, the 
response is temporary and tumour cells gain the ability to grow in an androgen-
deprived environment (Crawford, 1992). The cause or causes of development of 
androgen-independence has been subject of study for many years. Since most 
advanced tumours still contain AR, loss of expression is not likely a cause of therapy 
resistance (Culig et al., 1993; Hobisch et al., 1995). Suggested mechanisms implicated 
in development of androgen-independence include AR-activating mutations, AR 
amplification, altered expression and activity of AR co-activators or co-repressors or 
crosstalk with activated peptide growth factor receptor signalling pathways (Balk, 
2002; Shaffer and Scher, 2003).  
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AR mutations that change the sensitivity of the AR for androgens or other steroid 
hormones have been found, but clinical relevance has not been proven. Mutation rates 
vary from 0% to 50% in androgen-independent tumour samples (Evans et al., 1996; 
Suzuki et al., 1993; Taplin et al., 1995; Tilley et al., 1996). Another way to 
compensate for a low level of circulating androgens is AR gene amplification. Visakorpi 
et al. (Visakorpi et al., 1995) and Koivisto et al. (Koivisto et al., 1997; Visakorpi et al., 
1995)) found AR gene amplification in 30% of recurrent prostate cancers. In these 
studies, AR gene amplification correlated with increased expression of AR protein. 
Since AR gene amplification is found only in patients who had received ablation 
therapy, it was suggested that androgen withdrawal selects for cells that are more 
sensitive to low levels of circulating androgens (Trapman and Brinkmann, 1996). Next 
to androgens, other factors like peptide growth factors can also activate the AR and 
compensate in that manner for a low level of androgens (Ruijter et al., 1999). The 
following paragraphs will describe functions of peptide growth factors in normal 
prostate function and in prostate cancer. Furthermore, crosstalk between androgens 
and growth factor signalling pathways will be discussed.  
 
 
Figure 1.3. Possible mechanisms of AR activation in an androgen-deprived environment 
1. AR activating mutations enable the receptor to bind other ligands, e.g. anti-androgens, and to 
become activated. 
2. AR amplification/over-expression. More receptor molecules sensitise the cell for a low concentration 
of androgen. 
3. Over-expression of co-activators augments transcriptional activity of the AR in the presence of 
ligand. 
4. Crosstalk with other signal transduction pathways activates the AR via other mechanisms then 
ligand-binding. 
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1.2.3 Growth factor involvement in prostate cancer 
 
In normal prostate, growth factor pathways are regulated in a paracrine manner: 
stroma cells produce growth factors for which epithelial cells posses receptors (Russell 
et al., 1998). EGF, for example, is produced by stroma cells under the influence of 
androgens (Hiramatsu et al., 1988; Nishi et al., 1996) and binds the EGF receptor on 
epithelial cells. The epithelial cells depend on these factors for their growth and 
differentiation. However, in advanced stages of prostate cancer, when androgen level 
is low as a result of androgen ablation, epithelial cells may start to produce their own 
growth factors and become independent of androgen receptor activity (Cunha, 1994; 
Wong and Wang, 2000). Moreover, the tumour cells do no longer need the prostate 
environment and can metastasise outside the organ. Not only expression of peptide 
growth factors is altered in advanced prostate cancer, their receptors are also subject 
to changes (Djakiew, 2000). The best studied peptide growth factor-signalling pathway 
is that of EGF and its receptor. 
The EGF receptor is activated by a number of ligands, including EGF and TGF-α 
(Carpenter and Cohen, 1990; Massague, 1990). These two peptide growth factors are 
structurally related and, as they use the same receptor, their functions overlap. Both 
EGF and TGF-α switch from a paracrine to an autocrine regulation of EGF receptor 
activation during progression of prostate cancer and their expression becomes elevated 
(Ching et al., 1993; Fowler et al., 1988; Glynne-Jones et al., 1996; Harper et al., 
1993). EGF receptor expression also increases and has been correlated with increasing 
malignancy (Di Lorenzo et al., 2002). 
Although patient studies are inconclusive, androgen ablation has been shown to 
increase EGF receptor expression, while in normal prostate the receptor is down-
regulated by androgens (St-Arnaud et al., 1988; Traish and Wotiz, 1987). Interestingly 
EGF has been described to stimulate not only growth of cancer cells, but also the 
invasive capacity of prostate cancer cells is enhanced (Jarrard et al., 1994; Rajan et 
al., 1996). Other peptide growth factors implicated in prostate cancer development 
and progression include FGFs, IGFs (IGF1 and IGF2), NGF, PDGF, VEGF and TGF-β 
(Djakiew, 2000). In this thesis, the focus will be on EGF signalling and the involvement 
of this pathway in advanced prostate cancer.  
 
1.2.4 EGF signalling cascade 
 
The EGF transmembrane receptor is a member of a protein tyrosine kinase 
subfamily consisting of EGFR/ERBB, HER2/ERBB2, HER3/ERBB3, and HER4/ERBB4 
(Burgess et al., 2003; Roskoski, 2004; Ullrich and Schlessinger, 1990). After ligand 
binding, the EGF receptor forms a homodimer or dimerizes with one of the other 
members of the family (Wells, 1999). Dimerization activates the intrinsic kinase 
activity of the cytoplasmic tail of the receptor, which induces phosphorylation of the 
other member of the receptor pair and thus forms docking sites for cytoplasmic 
adaptor molecules (Yarden, 2001). Subsequently, these activated adaptors activate 
members of the RAS family. Dependent on cellular context, many effectors and 
pathways are known to be activated by the EGF receptor via RAS proteins. They 
include the mitogen-activated protein kinase (MAPK), the phosphoinositide 3-
phosphate lipid kinase pathway (PI3Kinase pathway), guanine nucleotide exchange 
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factors for the RAC1, RALA and RHO small GTPases, and many more (Pruitt and Der, 
2001; Wells, 1999).  
The activated MAPK (MEK) phosphorylates an extracellular (signal-) regulated 
kinase (ERK), which translocates to the nucleus. In the nucleus, ERKs activate 
transcription factors which induce transcription of genes that can play a role in 
proliferation, differentiation and migration (Garbay et al., 2000).  
The PI3Kinase pathway facilitates the conversion of phosphatidylinositol 4,5-
phosphate (PIP2) to phosphatidylinositol 3,4,5-phosphate (PIP3) which promotes 
activation of an AKT/PKB survival pathway. An important inhibitor of this pathway is 
the tumor suppressor PTEN (phosphatase and tensin homolog). PTEN is lost or 
mutated in many cancers, including prostate cancer (Li et al., 1997; Vlietstra et al., 
1998; Wang et al., 1998). Loss of PTEN expression constitutively activates the PI-
3Kinase pathway by phosphorylation of AKT, resulting in loss of susceptibility to 
induction of apoptosis by cytotoxic therapy or androgen-ablation (del Peso et al., 
1997; Kulik et al., 1997). It has been shown that in advanced stages of prostate 
cancer significantly more AKT is phosphorylated, compared to the earlier stages (Malik 
et al., 2002). Furthermore, androgen-ablation has been reported to increase the 
activity of PI3K and AKT (Murillo et al., 2001). Therefore, the PI3Kinase pathway 
seems to be essential for survival of prostate cancer cells in the absence of androgens 
(Lin et al., 1999). Since EGF activates the PI3Kinase pathway, autocrine activation of 
the EGF receptor may be a significant factor adding to the progression of prostate 
cancer from androgen-dependent to androgen-independent growth. 
 
 
 
 
 
 
 
 
 
Figure 1.4. EGF receptor signalling cascade 
The EGF receptor is activated by ligand binding. Consequently, depending on cellular context, diverse, 
partly overlapping signal transduction pathways are activated that lead to different cellular responses. 
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1.2.5 Crosstalk investigations 
 
To investigate possible roles that growth factors and androgens play in prostate 
cancer development, prostate cancer cell lines and animal models are helpful tools. An 
androgen-dependent and an androgen-independent cell line are essential to study the 
mechanisms of progression towards androgen-independence in vitro. One truly well-
characterised androgen-dependent human cell line available is the LNCaP cell line 
(lymph node carcinoma of the prostate) (Horoszewicz et al., 1980). This line contains a 
functional AR which harbours a mutation that broadens its ligand specificity. This 
mutated AR can be activated by oestrogens, progestins and antiandrogens (Grigoryev 
et al., 2000; Veldscholte et al., 1990). Many androgen-independent LNCaP sub-lines 
have been established (van Steenbrugge et al., 1989; Wu et al., 1994), providing 
suitable tools for studying progression of human prostate cancer. Another cell line with 
AR expression is CWR-R1, which is derived from the recurrent human prostate cancer 
xenograft CWR22 and is androgen-responsive (Gregory et al., 2001). CWR-R1 also 
contains a mutated AR that is different from the LNCaP mutation, but changes its 
characteristics similarly to the LNCaP mutation (Tan et al., 1997). Most prostate cancer 
cell lines are derived from metastatic lesions and are androgen-independent. PC3 
(Kaighn et al., 1979) and DU145 (Mickey et al., 1977) are well known and widely used 
androgen-independent cell lines. These lines do not express the AR and yield poorly 
differentiated tumours when injected into nude mice (Kaighn et al., 1979; Mickey et 
al., 1977; Tilley et al., 1990).  
 
 
Figure 1.5. Possible crosstalk mechanisms 
1. Activation of AR via phosphorylation by the MAPKinase pathway 
2. Regulation of AR-dependent transcription via activation or increased expression of specific 
transcription factors 
3. AR-mediated regulation of peptide growth factor expression and/or receptors 
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Normal prostate and early prostate cancer cells are dependent on androgens, but 
also on growth factors for homeostasis and growth (Russell et al., 1998). When 
prostate cancer cells are stimulated with androgens or EGF in vitro, they start to 
proliferate. Interestingly, when the cells are treated with EGF and androgens 
simultaneously, proliferation is stimulated synergistically, indicating that the AR and 
EGF receptor pathways influence each other (Guo et al., 2000; Schuurmans et al., 
1988a). It is possible that the AR directly influences EGF receptor signalling, but a 
mechanism where components of the EGF receptor signalling pathway activate the AR 
is also feasible (Grossmann et al., 2001) 
Reports on direct action of androgens on EGF signalling show that androgens 
stimulate expression of EGF by stromal cells in normal prostate, but not in prostate 
cancer where EGF is expressed in an autocrine manner in epithelial cells (Russell et al., 
1998; Sherwood and Lee, 1995). In agreement with this, expression of EGF was 
observed in the prostate cancer cell line LNCaP, but no increase in EGF expression by 
androgen treatment could be shown (Connolly and Rose, 1990). Androgens have also 
been reported to stimulate expression of EGF receptor (Schuurmans et al., 1988b), but 
data are conflicting because  there are also many reports indicating increased EGF 
receptor expression after androgen ablation (Di Lorenzo et al., 2002; Djakiew, 2000; 
Fiorelli et al., 1991). Despite these conflicting data, a detailed analysis of the changing 
pattern of expression of the EGF receptor and its ligands during progression of prostate 
cancer did indicate that a switch from paracrine to autocrine EGF signalling can play a 
role in the autonomous growth of androgen-independent prostate cancer cells (Scher 
et al., 1995). 
Effects of peptide growth factors on AR activity have also been reported. For 
example, EGF has been described to decrease AR expression (Mizokami et al., 1992). 
A more indirect effect of EGF on AR activation has been suggested by several other 
groups. Craft et al. (1999) and Cullig et al. (1994) reported that EGF simulates AR 
trans-activation in the absence of androgens, but in the presence of AR (Craft et al., 
1999; Culig et al., 1994). Gregory et al. (2003) showed that androgen-activated AR is 
required for EGF activation of AR trans-activation. This EGF-mediated AR activation is 
partly achieved via the MAPK pathway, since specific EGF receptor inhibitors or MAPK 
inhibitors can diminish the effect (Gregory et al., 2003).  
Induction of proliferation, next to AR trans-activation, has also been reported to 
result from crosstalk between EGF receptor- and AR-regulated pathways (Torring et 
al., 2003; Ye et al., 1999), although others report divergent stimulation of proliferation 
(Bell et al., 2003; Guo et al., 2000; Jones et al., 2001). Despite these investigations, 
the interaction between AR- and EGF receptor-mediated pathways is not fully 
understood, but many observations point towards an important role for both signalling 
pathways in regulation of prostate cancer growth. Changes in prostate cancer cells that 
activate these signalling pathways can give rise to a more aggressive phenotype. 
Proteins involved in androgen- or EGF-signalling that are either up- or down-regulated 
or mutated during progression of prostate cancer are therefore possible targets for 
intervention. Identification and functional studies of such proteins can explain their 
effect on progression of disease. 
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1.3 REPS2 and progression of prostate cancer 
 
Thus far, it is difficult to predict which prostate tumours will progress, and which 
will not. Therefore, reliable markers are needed to distinguish between relatively 
harmless well treatable tumours that will not progress and metastasise, and aggressive 
life-threatening tumours. Treatment of the former tumour type would not be 
necessary, whereas surgical removal of the latter should be performed as soon as 
possible. To determine proteins that are up- or down-regulated during progression of 
prostate cancer we used a technique called differential display. This technique is based 
on differences in mRNA content between two cell types. The flow chart of the 
technique is illustrated in Figure 1.6. 
 
Figure 1.6. Flow-chart of differential display analysis 
Two samples of RNA are isolated, e.g. one from cell type 1 and the other from cell type 2. After a reverse 
transcription procedure, where RNA is reverse transcribed into cDNA the two samples are analysed by 
electrophoresis. Differentially expressed cDNA bands are slices out and the sequences determined. 
 
REPS2 was identified in our laboratory, by differential display, from a 4 kb 
transcript down-regulated in androgen–independent compared to androgen-dependent 
prostate cancer cell lines and xenografts (Chang et al., 1997). The full-length cDNA of 
the transcript contains an open reading frame encoding a protein of 659 amino acid 
residues. The sequence of this clone revealed a 99% homology to the protein POB1 
(REPS2), and 60-80% homology to the functional domains of the human REPS1 
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protein. The REPS2 protein contains an EPS homology (EH) domain, a putative EH 
domain, a coiled-coil region and two proline-rich motifs (Ikeda et al., 1998; Koshiba et 
al., 1999). 
Figure 1.7. Functional domains of REPS2 
Linear map of REPS2. The position of EH domains, proline-rich regions, RALBP1 binding region and the 
coiled coil is indicated. 
 
These functional domains indicate a possible function of the protein.  
 Via the coiled-coil region, REPS2 binds RALBP1, a protein involved in inactivation of 
the small GTPases RAC1 and CDC42.  
 Via its two proline-rich regions REPS2 interacts with the growth factor receptor 
adaptor protein GRB2 (Ikeda et al., 1998).  
 The EH-domain of REPS2 was found to bind directly to EPN1 (Epsin1) and EPS15 
(Morinaka et al., 1999; Nakashima et al., 1999). EPS15 also contains EH domains 
and is involved in endocytosis of activated tyrosine kinase receptors (Santolini et 
al., 1999).  
 
1.3.1 Clathrin-mediated endocytosis of EGF receptor 
 
Many proteins with an EH-domain have been identified and shown to be involved in 
endocytosis (Santolini et al., 1999).  Endocytosis of activated tyrosine kinase receptors 
is mediated through formation of clathrin-coated pits and leads to receptor degradation 
or receptor recycling (Sorkin and Waters, 1993). Clathrin forms a triskelion of heavy 
and light chains, which organize together in cage-like structures. The whole process of 
clathrin coat formation is tightly regulated and involves a whole array of accessory 
proteins (Brodin et al., 2000). The main factor in the clathrin coat formation process is 
the adaptor-related protein complex 2, AP-2. This complex consists of four subunits, 
two large (α and β) and two small subunits (σ2 and µ2), and associates with clathrin 
and the other mediators of endocytosis. Clathrin interacts with the β subunit of AP-2 
(Ahle and Ungewickell, 1989), and EPS15, EPN1, amphiphysin, AP180, and auxilin 
interact with both the α-appendage and the β subunit (Owen et al., 2000; Pearse et 
al., 2000). Binding of activated EGF receptor to AP-2 initiates formation of the clathrin 
coated lattice, recruitment of accessory proteins and subsequent internalisation of the 
receptor (Santolini et al., 1999). EPS15 was shown to be involved in formation of the 
growing rim of the clathrin coat (Tebar et al., 1996) and to be essential for endocytosis 
of EGF receptors (Carbone et al., 1997).  
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Figure 1.8. Clathrin-mediated endocytosis 
After ligand binding, growth factor receptors are sequestered in clathrin-coated pits. This process is tightly 
regulated by many proteins like EPS15, EPN1, AP180, and many more. The pit is pinched off and becomes 
an early endosome. The receptor can then be either recycled back to the membrane, via a recycling 
endosome, or degraded via late endosomes and finally the lysosome. 
 
1.3.2 Endocytosis, growth factor signalling, REPS2 and prostate cancer  
 
Expression of REPS2, a binding partner of EPS15 and EPN1, is lost during prostate 
cancer progression. REPS2 also binds to GRB2 and RALBP1, which are also involved in 
internalisation (Jiang et al., 2003; Jullien-Flores et al., 2000; Martinu et al., 2002), and 
deletion mutants of REPS2 have been shown to inhibit endocytosis of EGF and insulin 
(Nakashima et al., 1999). These observations point towards involvement of REPS2 in 
receptor internalisation and to involvement of receptor internalisation in prostate 
cancer development. 
Internalisation of activated EGF receptor does not only lead to down-regulation of 
receptors and attenuation of signalling, but has also been implicated as essential for 
signal-transduction itself. For example, the adaptor protein GRB2 was found to be 
associated with activated EGF receptor and activated RAS proteins in the endosomes 
(Jiang and Sorkin, 2002). The subcellular localisation of activated growth factor 
receptors seems to determine which signal transduction pathways are activated and 
when (Burke et al., 2001). The specificity of these so-called signalling endosomes was 
shown by the fact that inhibition of endocytosis of EGF or insulin receptors by a 
dominant interfering mutant of dynamin results in inhibition of activation of the protein 
kinases ERK1 and ERK2, and in an increase of phospholipase Cγ activity (Ceresa and 
Schmid, 2000; Vieira et al., 1996).  
It appears that endocytosis is an essential component of efficient and accurate 
signalling of growth factor receptors. Furthermore, trafficking and signalling have been 
suggested to control each other in a feedback manner (Clague and Urbe, 2001). Many 
molecules involved in receptor endocytosis regulation are also able to activate EGF 
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signal transduction pathways. GRB2, RALBP1, EPS8, HGS, RAB5a and CBL are such 
molecules (Clague and Urbe, 2001; Di Fiore and Scita, 2002; McPherson et al., 2001; 
Urbe et al., 2000). REPS2 potentially possesses these qualities as well: involvement in 
endocytosis via EPN1 and EPS15, and involvement in EGF-signalling via RALBP1 and 
GRB2. Furthermore, expression of REPS2 is lost during prostate cancer progression 
and abnormal expression of endocytic proteins has been implicated in tumour 
development and mitogenic signalling (Di Fiore and Gill, 1999; Floyd and De Camilli, 
1998). 
Investigations performed to elucidate possible functions of REPS2 in signalling and 
internalisation of growth factor receptors, together with its possible involvement in 
prostate cancer progression, are described in Chapters 2 and 3.  
 
1.4 Microarray analysis  
 
Recently, microarray analysis, a new tool to analyse differences in mRNA 
expression between two conditions, was developed. The technique is bases on specific 
RNA expression in a certain sample. RNA expression profiles of, for example, healthy 
tissue and cancer tissue, or treated and untreated cell lines are measured and 
compared. This method allows comparison of expression levels of potentially all genes 
in the whole genome between different conditions in one single experiment. The flow 
chart of the technique is illustrated in Figure 1.9. In Chapters 4 and 5, this technique is 
used to determine the genetic differences between androgen-dependent and 
androgen-independent cells. Furthermore, crosstalk between androgen and growth 
factor receptor signalling pathways in prostate cancer progression is investigated. 
A well-performed microarray experiment leaves researchers with an enormous 
amount of data. Therefore, computerized methods have been developed for analysis. 
The software developed is diverse and new programs emerge almost every day. Since 
analysis of data is the key to reliable results, the principles will be discussed here. 
A microarray data analysis can be divided in 4 steps:  
1. Processing the raw expression data to acquire background and foreground signals 
of both channels and checking the quality of each spot. 
2. Normalizing the acquired red/green ratios in order to adjust for variation caused 
by other factors then differential expression. 
3. Pattern determination to find interesting groups of genes to analyse further. 
4. Annotation, to determine the function of selected genes and their possible 
relations. 
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Figure 1.9. Flow-chart of microarray analysis 
Two samples of RNA are isolated, e.g. one from treated and the other from untreated cells. After a reverse 
transcription procedure, where RNA is reverse transcribed into cDNA and the different dyes, Cy3 and Cy5, 
are incorporated, the two samples are hybridised to the microarray slide. After appropriate washing, the 
slides are then scanned and the generated data can be analysed after combining the two channels and 
normalization of the acquired signal intensities (Russo et al., 2003; Schulze and Downward, 2001). 
 
Step 1. Processing of the data comprises determination of foreground and 
background intensities of the Cy5 and Cy3 signals. The background signal is subtracted 
from the foreground signal, which results in a corrected value for either the Cy5 or Cy3 
signal of that spot. Background signals can be determined by several methods, either 
by defining the local background near the spots, or using a non-linear filter called the 
morphological opening, which determines the background at the actual spot location 
(Smyth et al., 2003). It is common practice to present expression data as a log2-
differential expression ratio (experimental signal/control signal). Many methods to 
determine spot quality have also been developed. The main purpose is to be able to 
flag unreliable spots, e.g. if the foreground signal is lower then the background signal 
or if the spot has a strange shape or distribution of pixel intensities. 
Step 2. Normalization corrects for distorted expression ratios caused by Cy5/Cy3 
bias, differences in printing tips, handling procedure, etc. The Cy5/Cy3 bias is caused 
by differences in labelling efficiency and scanning properties of the two dyes. The 
intensities of the Cy3 dye are often higher. Global normalization is widely used and 
correction is based on a constant difference between Cy5 and Cy3 signals that is 
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subtracted from the ratio. Generally, all genes on the array are used for normalization, 
based on the assumption that the summation of the expression ratios between control 
and experimental sample is close to zero. This holds true for a test where the 
difference between experimental and control samples is small and the differentially 
expressed genes are distributed symmetrically. The use of so-called housekeeping 
genes, which have constant expression levels between samples, is another method for 
normalization, but the definition of these genes might be a problem (Yang et al., 
2001). Global normalization, although widely used, is not always the best method. This 
correction method is simplified, while more sophisticated ways of correction, based on 
location, spot intensity, and background values have been developed and proven to be 
valid (Kim et al., 2002).  
Step 3. When reliable ratios are acquired, the data can be used to start to unravel 
the biological meaning behind the experiment. The first step is to organize the list of 
primary data, often consisting of expression ratios for tens-of-thousands of genes in a 
large number of experiments. A natural way to analyse and visualize the data is cluster 
analysis. Clustering involves grouping together genes that behave similar in time or 
between different conditions, and therefore have similar expression patterns. The 
method is based on maximizing the intra-class similarity and minimizing the inter-class 
similarity. Next to organizing and reordering the gene list, clustering software is 
designed to visualize the results in a typical manner. Genes are depicted with a colour, 
which reflects the expression ratio, qualitatively and quantitatively. Furthermore, the 
relationships between genes is represented by a tree, the distance between the 
branches correlates with the distance or similarity between genes. Genes with similar 
expression patterns, and ideally similar function, are therefore clustered together, 
have similar colour and are adjacent in the tree (Eisen et al., 1998).  
Many clustering methods and software exists, based on all kinds of classifiers, 
hierarchical clustering, k-means clustering, graph-theoretic clustering or self-
organizing maps, etc. (Quackenbush, 2001; Raychaudhuri et al., 2001). To obtain 
reliable results, the use of a combination of several clustering methods might be ideal 
(Kaminski and Friedman, 2002). In the end, cluster analysis is a tool to provide 
biologists with visual graphics instead of large lists and tables, to be able to determine 
what genes to focus on in further research.  
Step 4. To obtain meaningful biological results, the function of the selected groups 
of genes has to be determined. Again, many tools for annotation of large sets of genes 
have been developed. These are based either on gene ontology like GenMAPP and 
MaPPFinder (Dahlquist et al., 2002; Doniger et al., 2003) or on co-appearance in 
literature like PubGene (Jenssen et al., 2001). Development of such tools is still in 
progress and needs integrated knowledge of different professionals. Computer 
technology, biological information, statistic tools, and laboratory experience have to be 
combined to engage the challenge of microarray analysis fully. 
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Figure 1.10. Hierarchical cluster analysis 
A. Example of a generated cluster diagram. The columns represent the different experiments, and the 
rows represent the different genes.  
B. Colour legend. The colour reflects the expression ratio, qualitatively and quantitatively. 
 
1.5 Aims and outline of this thesis 
 
Prostate cancer progression involves a switch from androgen-dependence to 
androgen-independence. Genetic differences between these states have been subject 
of research for many years. New tools have been developed to determine differentially 
expressed genes, but eventually the function of these genes and their functional 
interconnection determines the value for therapy. Genes with a differential expression 
pattern can be used for diagnostic means and for intervention. The protein REPS2 was 
found with a conventional technique, differential display, as a transcript for which 
expression was lost in androgen-independent prostate cell lines and xenografts (Chang 
et al., 1997). Concerning this protein we asked the following question, which is 
addressed in Chapters 2 and 3. 
 
1. Via which mechanisms does loss of expression of the endocytosis protein REPS2 
contribute to an androgen-independent phenotype of prostate cancer cells? 
 
The involvement of growth factors like EGF in prostate cancer progression is 
evident (Russell et al., 1998). Since REPS2 is involved in EGF signalling and also 
implicated in prostate cancer progression, the impact of this signalling molecule on 
invasion and proliferation of androgen-dependent prostate cancer cells was 
investigated. Furthermore, possible crosstalk between androgen- and growth factor 
signalling pathways in these cells was studied. Proliferation and invasion were 
examined, both biologically and with microarray analysis of androgen-dependent 
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prostate cancer cells treated with androgens or EGF, addressing the following 
questions (Chapter 4):  
 
2. Is it possible to identify genes, activated by androgens or EGF, that induce 
proliferation and invasion of prostate cancer cells? 
3. Do EGF- and androgen-signalling overlap in prostate cancer cells and if so, to 
what extent? 
 
We were also interested in the mechanisms that control androgen-independent 
proliferation of prostate cancer cells. Therefore, microarray analysis was performed on 
androgen-dependent and androgen-independent prostate cancer cells treated with 
androgens or EGF. Using the generated dataset, the following questions were dealt 
with (Chapter 5): 
 
4. What are the differences between androgen-dependent and androgen-
independent cells in gene-expression and hormonal control of gene-regulation?  
5. Can expression analysis provide insight in how androgen-independent cells 
proliferate without addition of androgens or EGF? 
 
In Chapter 2 the differential expression of REPS2 between androgen-dependent 
and androgen-independent prostate cancer cells, and the effect of the REPS2 protein 
on cell growth and signalling is described. 
In the experiments described in Chapter 3 the involvement of endocytosis of EGF 
receptor in prostate cancer progression and the effect of REPS2 on that process is 
investigated. 
In Chapter 4 the effect of androgen and EGF on proliferation and invasion of 
prostate cancer cells is described. Additionally, microarray analysis of EGF-treated 
prostate cancer cells was performed and compared to publicly available microarray 
datasets of androgen-treated prostate cancer cells and prostate cancer patient 
samples. 
In Chapter 5 microarray analysis is described of androgen-dependent and 
androgen-independent LNCaP cells treated with androgens or EGF. The differences 
between these cell lines in gene expression and gene regulation is investigated in the 
context of regulation of cell proliferation. 
The results of these investigations, in the context of the above questions, are 
discussed in Chapter 6. 
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Abstract 
 
During progression of prostate cancer, cellular changes occur, leading to a transition 
from androgen-dependent to androgen-independent growth. One aspect of this 
transition is a switch from androgens to growth factors, like epidermal growth factor 
(EGF), as primary regulators of proliferation. We examined the involvement of 
REPS2/POB1 in this process. REPS2/POB1 is an EH domain-containing protein, 
reported to be involved in signalling via RALBP1 and to play a role in endocytosis of 
EGF receptors. Furthermore, the protein is relatively highly expressed in androgen-
dependent as compared to androgen-independent human prostate cancer cell lines and 
xenografts. 
 Next to the known REPS2/POB1 protein, an open reading frame encoding 
REPS2/POB1, with 139 additional amino acid residues at the NH2-terminus, was cloned 
and found to be expressed in prostate cancer cells. Overexpression, by transient 
transfection, of both forms of REPS2/POB1 in prostate cancer cell lines, induced 
apoptosis within 48 hours. At shorter time intervals after transfection, signalling 
towards a TPA response element (TRE) luciferase reporter was found to be inhibited. 
From these experiments, it is concluded that REPS2/POB1, through its influence on the 
RAL signalling pathway, is involved in growth factor signalling. Decreased expression of 
REPS2/POB1 during progression of prostate cancer may therefore result in loss of 
control of growth factor signalling and consequently in loss of control of cell 
proliferation.  
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Introduction 
 
The transition from androgen-dependent to androgen-independent growth during 
prostate cancer progression is of great concern, since androgen-independent tumours 
are incurable. One possible mechanism underlying this transition is a switch from 
androgens to growth factors as primary regulators of prostate cancer cell proliferation. 
Fibroblast growth factors (FGFs), insulin-like growth factors (IGFs) and epidermal 
growth factor (EGF) are examples of autocrine factors which stimulate growth of 
advanced, androgen-independent, prostate cancer (Russell et al., 1998). For EGF, 
binding of the ligand to the receptor induces cell proliferation by activating well-
characterised signal transduction pathways that involve phosphorylation and activation 
of mitogen-activated protein kinases (MAPKs). The activation of the GTP-ase RAS is 
one of the initial steps in EGF signalling, and once RAS is activated, it can facilitate 
activation of the serine/threonine kinase RAF, PI3-kinase and RALA-GEF, a guanine 
nucleotide exchange factor which activates the small GTP-ase RALA (reviewed by 
(Pruitt and Der, 2001). Activated RALA binds to RALBP1, which exhibits GAP (GTPase 
activating protein) activity towards CDC42 and RAC1 (Cantor et al., 1995; Jullien-
Flores et al., 1995; Park and Weinberg, 1995). 
REPS2/POB1 is a protein partner of RALBP1, contains a single EH domain, two SH3 
binding sites and several other functional regions (Ikeda et al., 1998). REPS2/POB1 
has been implicated in endocytosis and signal transduction (Ikeda et al., 1998; Kariya 
et al., 2000; Nakashima et al., 1999) and is currently evaluated for its putative role in 
prostate cancer progression.  
 
Endogenous expression of REPS2/POB1 in prostate cancer cell lines 
 
In a previous study, reduced mRNA expression of REPS2/POB1 was found in the 
androgen-independent human prostate cancer cell lines PC3, DU145 and LNCaP-LNO, 
as compared to the expression level in the androgen-dependent LNCaP-FGC cell line. 
In addition, using a panel of human prostate cancer xenografts, REPS2/POB1 
expression was also found to be markedly reduced in androgen-independent prostate 
cancer xenografts (Chang et al., 1997).  
Using a hypothalamus cDNA library, a 1987 bp cDNA clone was obtained containing 
an open reading frame encoding a protein of 659 amino acid residues. This protein 
consists of the published coding region of REPS2/POB1 (accession number AF010233) 
minus one glutamine at position 43, and 139 additional amino acid residues at the 
NH2-terminal end (Figure 2.1A). All reported studies so far, however, made use of the 
shorter 521 amino acid REPS2/POB1 protein. We examined the possible translation of 
the extended REPS2/POB1 protein in human cells using a specific REPS2/POB1 
antibody and were able to detect 78 kDa and 58 kDa protein bands in lysates from 
prostate cancer cell lines (Figure 2.1B). These results indicate that, both the 659 
amino acid residue, and the 521 amino acid residue REPS2/POB1 protein are 
expressed in these cell lines.  
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Figure 2.1. Analysis of endogenous REPS2/POB1 expression in prostate cancer cell lines  
The LNCaP-FGC (passage number 22-30) and LNCaP-LNO (passage number 78-100) cell lines, were kindly 
provided to us by Dr. J.S. Horoszewicz (Buffalo, NY). The LNCaP-FGC cell line is identical to the one which 
can be obtained from the American Type Culture Collection (Rockville, MD). LNCaP-FGC, LNCaP-LNO, PC3 
and DU145 cells were maintained at 37°C in a 5% CO2 atmosphere in RPMI 1640 plus 5% v/v fetal calf 
serum (FCS) or serum depleted of steroids by dextran-coated-charcoal (DCC) treatment (van Steenbrugge 
et al., 1991). The LNCaP-LNO cell line has been derived from an early passage (6th) of the parental 
LNCaP-FGC cell line (Horoszewicz et al., 1980).(A) Linear map of REPS2/POB1 (1-659) and REPS2/POB1 
(140-659), indicating the relative location of EH domains, proline-rich regions, RALBP1 binding region, and 
predicted coiled coil. (Adapted from Ikeda et al. 1998) (B) Western blot analysis of lysates of LNCaP-FGC 
passage numbers 26 and 28 (lanes 1 and 2), LNCaP-LNO (lane 3), PC3 (lane 4) and DU 145 (lane 5) after 
7% SDS-PAGE, showed REPS2/POB1 down-regulation in androgen-independent prostate cancer cell lines. 
The antiserum was generated by immunising rabbits with two REPS2/POB1 peptides; peptide 1: amino 
acid residues 446-461 and peptide 2: amino acid residues 566-580, and then affinity-purified. The arrows 
point at the two REPS2/POB1 protein forms. (C) Northern blot analysis of REPS2/POB1 mRNA expression 
in prostate cancer cell lines. Total RNA of LNCaP-FGC (lane 1), LNCaP-LNO (lane 2), PC3 (lane 3) and DU 
145 (lane 4), was hybridized with a REPS2/POB1 cDNA probe. 
 
An other argument in favour of the co-existence of a longer REPS2/POB1 protein, is 
the observation that the translation start sequence, proposed by Kozak (Kozak, 1987), 
is more consistent with the sequence around the more 5' ATG, described herein, then 
the translation start sequence of REPS2/POB1 described by Ikeda et al. (1998) (Figure 
2.2A). Furthermore, the additional 139 NH2-terminal amino acid residues form a 
putative second EH domain (Figure 2.2B) and this amino acid sequence exhibits high 
homology with the mouse Reps1 and human REPS1 proteins (72% identity). Whether 
both REPS2/POB1 products are formed by alternative first ATG usage or alternative 
pre-mRNA splicing, is currently unknown. We observed a good correlation between 
mRNA and protein expression of REPS2/POB1 in DU145, PC3, LNCaP-FGC and LNCaP-
LNO cells. The LNCaP-FGC cells were found to express REPS2/POB1 mRNA and protein 
at relatively high levels, whereas LNCaP-LNO and DU145 cells do not express 
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detectable levels of REPS2/POB1 mRNA and protein. The PC3 cells show low 
expression of REPS2/POB1 protein and no detectable expression of REPS2/POB1 mRNA 
(Figure 2.1B and 2.1C).  
Figure 2.2. Sequence properties of REPS2/POB1 cDNA  
(A) Comparison of translation start site of REPS2/POB1 and REPS2/POB1(140-659) with the start site 
proposed by Kozak (Kozak, 1987). (B) Alignment of several EH domains. REPS2_EH1 is the EH domain 
found in the first 139 amino acid residues of REPS2/POB1. Also presented are: REPS2_EH2: REPS2/POB1 
(275-364); Eps15_EH3: EPS15 (218-313); Eps15R_EH: EPS15R (13-103); Inters_EH1: Intersectin2 (28-
118) and Eps15_EH1: EPS15 (16-103). Amino acids shared between more than 50% of the EH domains 
are in italics, between more than 75% are underlined and 100% alignment is shown in bold. All sequences 
are from human. Sequences were aligned using the DNAMAN program.  
 
Role of REPS2/POB1 in signal transduction: apoptosis 
 
To determine the cellular localisation of REPS2/POB1 in prostate cancer cells, LNCaP-
FGC and LNCaP-LNO cells were transiently transfected with cDNA encoding 
REPS2/POB1 or REPS2/POB1(140-659), fused to GFP. Cells were analysed with 
fluorescence microscopy at different time points after transfection. It was observed 
that both variants of REPS2/POB1 mainly reside in the cytosol and not in the nucleus 
(Figure 2.3A). Subsequently, the cells were subjected to prolonged expression of GFP-
tagged REPS2/POB1, REPS2/POB1(140-659) or part of the androgen receptor (AR), to 
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examine the effect of REPS2/POB1 and REPS2/POB1(140-659) on prostate cancer cell 
growth. The tagged AR was used to evaluate non-specific effects of the transfection 
procedure. REPS2/POB1 was found to induce programmed cell death. Transfected cells 
which showed DNA fragmentation and cell membrane damage, as observed using 
Hoechst and propidium iodide staining were considered to be apoptotic (Figure 2.3B-
D). REPS2/POB1(140-659) or REPS2/POB1 induced apoptosis in 45% of transfected 
cells already within 48 hours and up to 60% after 96 hours (Fig 2.3E). Based on these 
observations, a regulating role for REPS2/POB1 in a signalling pathway that controls 
apoptosis was hypothesised.  
Figure 2.3. Induction of apoptosis after transfection with REPS2/POB1-GFP 
REPS2/POB1 and REPS2/POB1(140-659) cDNA was obtained from a human brain, thalamus 5'-stretch plus 
cDNA library (Clontech) and cloned into the pEGFP-N2 vector (Clontech) between the Xho1 and Kpn1 sites. 
Deletion mutant REPS2/POB1 (1-373) and REPS2/POB1 (451-659) were synthesised by PCR and ligated in 
pEGFP-N2. pEGFP-∆AR consists of a HindIII fragment of the cDNA encoding the NH2-terminal part of the 
androgen receptor (AR), cloned into pEGFP-N2. LNCaP-FGC cells transfected with cDNA encoding 
REPS2/POB1-EGFP, ∆AR-EGFP or EGFP alone (1µg/ml medium) were analysed by fluorescence microscopy. 
(A) For localisation of the REPS2/POB1-EGFP product, LNCaP cells transfected with pEGFP-RESP2/POB1 
were studied using confocal laser scanning microscopy. LNCaP-FGC cells transfected with REPS2/POB1-
EGFP show cytoplasmic localisation of REPS2/POB1-EGFP. (Magnification: 100x). Analysis after 72 hours 
of transfection with REPS2/POB1-EGFP with fluorescence microscopy. (B) Hoechst 33342 staining, (C) 
Propidium iodide staining (D) REPS2/POB1-EGFP expression. (Magnification: 40x). (E) Cells with positive 
Hoechst and propidium iodide fluorescence were quantified as a percentage of EGFP positive cells at 
different time points after transfection. (F) Apoptosis induction by deletion mutant constructs of 
REPS2/POB1 fused to GFP quantified as a percentage of EGFP positive cells, at different time points after 
transfection. The results shown are the mean ± SD of three independent experiments; each experiment 
included two independent culture plates.  
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We investigated whether the role which REPS2/POB1 seems to play in induction of 
apoptosis can be explained when the function of one of its binding partners, RALBP1, is 
implicated. When we transfected LNCaP cells with a deletion mutant of REPS2/POB1 
lacking the RALBP1 binding domain (1-373), only 30-40% of the transfected cells 
became apoptotic (72-96 hours), while a mutant containing only the RALBP1 binding 
domain of REPS2/POB1 (451-659), induced apoptosis in 40-75% of the transfected 
cells (Figure 2.3F). Since the expression levels of the two proteins were similar, these 
observations suggest that the RALBP1 binding properties of REPS2/POB1 are at least 
partly responsible for apoptosis induction in these cells. 
RALBP1 is a protein with GAP (GTPase activating protein) activity towards RAC1 and 
CDC42 (Cantor et al., 1995; Jullien-Flores et al., 1995; Park and Weinberg, 1995). 
Activated RAC1 and CDC42 have been implicated in signalling towards cell survival 
(Joneson and Bar-Sagi, 1999; Osada et al., 1999) and, because of its GAP activity, 
RALBP1 is capable of inhibiting these functions. The GAP activity of RALBP1, in turn, 
can be inhibited by activated RALA, which translocates RALPB1 to the cell membrane 
and physically away from RAC1 and CDC42 (Matsubara et al., 1997). The presence of 
REPS2/POB1, as a cytosolic protein, may in this respect function to counteract 
activated RALA, maintaining a number of RALBP1 molecules in the cytosol and thus 
available to inactivate RAC1 and CDC42. Overexpression of REPS2/POB1 may result in 
a strong inhibition of RAC1 and CDC42 signalling, which may consequently result in the 
observed induction of apoptosis. 
The deletion mutant that lacks the RALBP1 binding domain also induces apoptosis, 
but less efficient, suggesting that the two EH domains of REPS2/POB1 may also play a 
role. The C-terminal EH domain of REPS2/POB1 binds to EPS15 and Epsin and is 
involved in internalisation of growth factor receptors (Nakashima et al., 1999). 
Disruption of endocytosis might lead to improper signal transduction and consequently 
to cell death. For example, it has been reported that inhibition of endocytosis of EGF 
receptors or insulin receptors by a dominant interfering mutant of dynamin results in 
inhibition of the activation of the protein kinases ERK1 and ERK2, emphasising the 
importance of signalling during and after endocytosis.  
 
Role of REPS2/POB1 in signal transduction: inhibition of signalling 
It has been described that RAC1 and CDC42 are involved in activation of JUN (Coso 
et al., 1995) and heterodimers of JUN and FOS activate, among others, genes 
controlled by promoter sequences containing a TRE (TPA response element) (Angel et 
al., 1987). A phorbolester responsive reporter system (5xTRE luciferase reporter) was 
used to investigate the effect of transient REPS2/POB1 expression in the human 
prostate cancer cell line PC3. The TRE reporter can be activated by several growth 
factors (including EGF), serum and synthetic compounds like phorbol esters. Since PC3 
cells are not very sensitive to EGF (Janssen et al., 1995), 15% v/v fetal calf serum was 
used to activate transcription of the luciferase reporter gene. It was observed that 
luciferase transcription was increased approximately 8-12 fold over control expression 
by addition of serum. Furthermore, short term transfection (24 hours) with increasing 
amounts of REPS2/POB1 cDNA/well inhibited serum-induced activation of the TRE 
reporter. Using 10, 30 and 100 ng REPS2/POB1 cDNA/well, a 46%, 80% and 90% 
reduction in luciferase activity was observed, respectively, compared to mock-
transfected cells (Figure 2.4). This reduction in luciferase activity was not a result of 
REPS2/POB1-induced apoptosis and a decreasing cell number, because apoptosis is not 
observed at 24 hours after transfection.  Furthermore, in a parallel transfection assay, 
where a RSV-luciferase reporter was used, no significant inhibition of luciferase activity 
was observed with increasing amounts of REPS2/POB1 cDNA. These results indicate 
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that overexpression of REPS2/POB1 exerts a marked inhibitory effect on serum-
induced signalling to a TRE reporter. 
Figure 2.4. Effect of REPS2/POB1 on TRE-Luc activation in PC3 cells 
pcDNA3.1-REPS2/POB1 was constructed from pEGFP-RESP2/POB1. REPS2/POB1 cDNA was cloned into 
pcDNA3.1 (Invitrogen). between the Nhe1 and Kpn1 sites. 5xTRE-TATA-Luc was constructed from 5xTRE-
TATA-CAT6 (a gift from Dr. A. Cato, Karlsruhe, Germany). PC3 cells were cotransfected with 50ng TRE-Luc 
plasmid DNA, in combination with 0, 10, 30 or 100 ng of psDNA3.1-REPS2/POB1 or the empty pcDNA3.1 
vector. Stimulation with 15% FCS was started immediately after the start of transfection, and luciferase 
activity was determined at 24 hours with the Topcount NXTTM microplate luminescence counter (Packard 
Bioscience BV; Meriden, CT, USA). The total amount of DNA in each transfection was normalised using 
pTZ19U plasmid (US biochemical). The results are expressed relative to the level of luciferase activity in 
cells cotransfected with the empty vector and the TRE-Luc vector after stimulation with serum. The mean 
± SD of an experiment performed in triplicate is shown. Similar results were observed in two independent 
experiments. 
 
In advanced prostate cancer cells, the expression status of REPS2/POB1 does not 
represent overexpression, but rather loss of expression. Consequently, the inhibiting 
activity of RALBP1 on RAC1 and CDC42 may be compromised, resulting in loss of 
control of cell survival and consequently mitogenic signalling. 
It is concluded that loss of REPS2/POB1 expression, which occurs during 
progression of prostate cancer, results in dysregulation of growth factor signalling. This 
can be the result of loss of the interaction of REPS2/POB1 with RALBP1 or the result of 
loss of function of REPS2/POB1 during growth factor receptor internalisation. 
Furthermore, it is also possible that both mechanisms simultaneously play a role in 
REPS2/POB1-induced dysregulated growth factor signalling. Since RALBP1, like 
REPS2/POB1, has also been reported to be involved in endocytosis (Jullien-Flores et 
al., 2000), effects of REPS2/POB1 on endocytosis, via binding to RALBP1, and then on 
signal transduction, can not be excluded. Furthermore, it has been described that 
dysregulated endocytosis can lead to mitogenic signalling, and that mutation or 
abnormal expression of endocytic proteins is implicated in tumour development (Di 
Fiore and Gill, 1999; Floyd and De Camilli, 1998). Further research utilising stable 
inducible cell lines expressing REPS2/POB1 at a more physiological level, will be used 
to unravel the precise role of REPS2/POB1 in signalling and endocytosis. 
Taken all data together, there is evidence to suggest that loss of REPS2/POB1 
expression, during progression of prostate cancer, results in loss of control of cell 
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growth signalling. This can be a direct effect through RALBP1 or an indirect effect via a 
function in growth factor internalisation. Further investigations of the role of 
REPS2/POB1 in control of prostate cancer progression are important to improve our 
understanding of androgen-independent tumour growth.  
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Abstract 
 
In advanced prostate cancer, cellular changes occur leading to a transition from 
androgen-dependent to androgen-independent growth. During this transition, 
proliferation of androgen-dependent prostate cancer cells becomes more and more 
dependent on growth factors, like the epidermal growth factor (EGF). Endocytosis of 
growth factor receptors, one of the mechanisms that controls growth factor signalling, 
was observed to be markedly changed in advanced metastatic prostate cancer. 
Internalisation and signalling of EGF receptors was examined in different prostate 
cancer cell lines, in relation to the expression level of the endocytosis-related REPS2 
gene. It was observed that a high level of REPS2 correlates with reduced EGF-
internalisation. To investigate this more thoroughly, prostate cancer cells with inducible 
REPS2 expression were generated. Using these cells, it was found that REPS2 induction 
indeed results in reduction of EGF internalisation. Furthermore, when EGF receptor 
signalling was evaluated, by examination of mRNA expression for several EGF-
responsive genes (EGF receptor, EGR-1, FOS, JUN), it was observed that induced 
expression of REPS2 exerts an inhibiting effect on this signalling. 
From these experiments, it is concluded that increased REPS2 expression negatively 
affects EGF receptor internalisation and subsequent signalling. Therefore, decreased 
REPS2 expression during prostate cancer progression, observed in earlier work, may 
result in enhanced EGF receptor expression and signalling, which could add to the 
androgen-independent state of advanced prostate cancer. 
 REPS2 inhibits EGF-signalling 
51 
Introduction 
 
Treatment of prostate cancer involves surgery of the affected region of the gland 
and treatment of advanced prostate cancer focuses on inhibition of growth inducing 
signals, mainly by androgen ablation. However, given enough time, the tumour is 
suggested to switch from androgens to growth factors as primary regulators of 
proliferation. This transition leads to therapy-resistance of the cancer cells and 
eventually will result in recurrence of the disease (Russell et al., 1998).  
Epidermal growth factor (EGF) and transforming growth factor alpha are potent 
mitogens involved in autocrine regulation of proliferation, angiogenesis and metastatic 
spread of advanced prostate cancer (Scher et al., 1995). The EGF receptor can bind 
many ligands, among which EGF and TGF-α (Jones et al., 1999). Upon ligand-binding 
the receptor dimerizes and is activated by autophosphorylation of tyrosine residues in 
the intracellular tail of the receptor. Subsequent activation of well-characterized signal 
transduction pathways (MAPK) results in proliferation and survival of tumour cells 
(Gullick and Srinivasan, 1998; Yarden, 2001). 
During prostate cancer progression, the EGF receptor expression level is regulated 
by transcriptional and post-transcriptional mechanisms, including up-regulation of 
receptor mRNA and down-regulation of EGF receptor protein by EGF. Intracellular 
trafficking of the EGF receptor was suggested to cause the overall degradation of the 
EGF receptor protein in prostate cancer cells (Seth et al., 1999). This trafficking 
involves endocytosis of receptor-ligand complexes in clathrin-coated pits and 
subsequent degradation of these complexes in endosomes. Furthermore, in contrast to 
degradation, active signalling complexes are also newly formed during endocytosis (Di 
Fiore and Gill, 1999; Waterman and Yarden, 2001). Endocytosis is reported to be an 
essential component of efficient and accurate signalling of growth factor receptors 
(Ceresa and Schmid, 2000).  
Dhanasekaran et al. (2001) published a large set of cDNA array analyses of a 
commercial pool of normal prostate tissues compared to normal human prostate, 
prostate hyperplasia, prostate cancer, and prostate cancer metastasis samples. In 
Table 3.1 we have summarized a selection of genes from the prostate cancer 
expression data set, for which it is known from literature that these genes are involved 
in growth factor receptor endocytosis. Of these 15 genes, 8 showed a differential 
expression between the normal prostates and the four investigated metastasis group in 
the Dhanasekaran data-set. Interestingly, except for amphiphysin, these endocytosis-
related genes were down-regulated during metastasis, while in non-metastatic 
prostate cancer samples some genes were down-regulated while others were not 
regulated compared to expression in normal prostate. These data indicate that the 
process of endocytosis is subject to changes during development of metastatic 
prostate cancer, and suggests a role for altered endocytosis in metastasis. 
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Table 3.1. Functions of endocytosis-related genes and their expression in metastatic 
prostate cancer tissues as compared to normal prostate tissues.  
 
 
Protein name Function in endocytosis 
Expression in metastasis 
versus normal 
AP-2 Coat protein; recruitment of other proteins Down 
Endophilin Invagination of the coated membrane Down 
CALM Clathrin coat assembly Down 
Amphiphysin Fission of clathrin coated pits Up 
RAB5a Regulation of trafficking Down 
Dynamin 2 Fission of clathrin coated pits Down 
Intersectin 1 Fission of clathrin coated pits Down 
Caveolin 2 Caveolar exit Down 
NUMB Clathrin coat assembly (possible) No change 
Neuronal SHC Routing of activated receptors No change 
Synaptotagmin Clathrin coat assembly No change 
Clathrin L Coat protein No change 
RALBp1 Clathrin coat assembly No change 
EPS15 Clathrin coat assembly No change 
Clathrin H Coat protein No change 
 
Genes were selected from cDNA array analyses, which were made available to the public by 
Dhanasekaran et al., 2001. Genes were considered to be up- or down-regulated when the fold 
change was at least 1.4. 
 
Several proteins control endocytosis and subsequent intracellular trafficking. One of 
the essential regulatory proteins is EPS15 (Epidermal growth factor receptor pathway 
substrate 15). EPS15 binds to AP2 (adaptor protein complex 2) at the growing rim of 
the invaginating pit, and interacts with other endocytic proteins such as Epsin, 
Intersectin, and POB1 or REPS2 (Waterman and Yarden, 2001). The REPS2 protein 
contains a coiled-coil region, two proline-rich motifs and an EH domain (EPS15 
homology domain). The two proline rich regions of REPS2 have been shown to interact 
with the growth factor receptor adaptor protein GRB2 (Ikeda et al., 1998) and the EH-
domain of REPS2 was found to bind directly to Epsin and EPS15 (Kariya et al., 2000). 
Interestingly, GRB2 has also been identified as a regulator of EGF receptor endocytosis 
(Martinu et al., 2002). Based on these observations and the finding that expression of 
deletion mutants of REPS2 inhibits internalisation of EGF and insulin, REPS2 was 
suggested to be involved in growth factor receptor signalling and regulation of 
endocytosis (Nakashima et al., 1999)  
In a previous study, reduced expression of REPS2 was found in androgen-
independent human prostate cancer cell lines and xenografts, as compared to a 
relatively high expression level in androgen-dependent cells and xenografts (Chang et 
al., 1997). Furthermore, over-expression of REPS2 in prostate cancer cells inhibits 
growth factor signalling, and results in induction of apoptosis (Oosterhoff et al., 2003).  
To begin to understand if and how changes in the process of endocytosis might 
influence development of metastatic prostate cancer, the present investigation was 
focused on internalisation and signalling of the EGF receptor in relation to the 
expression level of REPS2. It was observed that REPS2 inhibits EGF signal 
transduction, possibly by reducing the rate of EGF receptor endocytosis. These data 
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provide further support for the hypothesis that loss of REPS2 expression during 
prostate cancer progression directly impacts on growth factor signalling. This 
stimulation of growth factor signalling can contribute to maintenance of androgen-
independent growth. 
 
Material and Methods  
 
Materials and cell culture 
Cell culture flasks and plastic disposables were obtained from Fisher Scientific 
(Houston, TX, USA). RPMI 1640 and culture chemicals were purchased from Gibco 
Invitrogen Corporation (Carlsbad, CA, USA). Foetal calf serum (FCS) was from Greiner 
(Frickenhausen, Germany). Restriction and modifying enzymes were obtained from 
Roche (Indianapolis, IN, USA). Tetramethylrhodamine-conjugated EGF (EGF-
rhodamine) was purchased from Molecular Probes (Eugene, OR, USA). 125I-EGF was 
obtained from Amersham Biosciences Corp (Piscataway, NJ, USA). Receptor grade EGF 
from mouse submaxillary glands was provided by Sigma (Saint Louis, MI, USA). Anti-
EGF receptor antibody (1005) and anti-phosphorylated tyrosine antibody were 
obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-REPS2 polyclonal 
and immunoaffinity purified antibody was manufactured as described (Oosterhoff et 
al., 2003). Horseradish peroxidase-conjugated anti-rabbit and anti-mouse antibodies 
were from Sigma (St. Louis, MI, USA). ECL detection reagents were from Perkin Elmer 
(Wellesley, MA, USA). Cells were maintained as described (Oosterhoff et al., 2003). 
 
Plasmid constructions 
REPS2-GFP was subcloned as described (Oosterhoff et al., 2003). For stable 
inducible transfection we used the ecdyson-inducible expression kit (Invitrogen, 
Carlsbad, CA, USA). REPS2 cDNA was cloned into the pIND/Hygro vector, using Kpn I 
and Xba I restriction sites. 
 
125I-EGF binding and internalisation assay 
Prostate cancer cells (DU145, PC3, PC3-R2 and LNCaP-FGC), were grown 
subconfluent (90%) in 6 wells plates. Cells were serum starved overnight and washed 
in binding buffer (RPMI, supplemented with 20mM HEPES pH7.4, and 0.1% BSA). Cells 
were incubated with excess EGF,  by adding mixtures containing 5 ng/ml 125I-EGF 
(specific activity: 3 – 4.5 MBq/µg) and 10ng/ml unlabeled EGF, for 60 minutes at 4°C. 
Cells were then either transferred to 37°C, for 10 or 45 minutes, or directly washed 
twice with ice-cold phosphate-buffered saline, to establish binding at 0 min. To remove 
membrane-bound 125I-EGF the cells were washed twice with ice-cold acid buffer (25mM 
NaOH/ acetic acid, pH 3.8 and 150mM NaCl) and subsequently with PBS. Cells were 
lysed in 1N NaOH and radioactivity was determined by counting in a γ-counter (Cobra 
Quatum, Perkin Elmer, Boston, MA, USA). To determine bound EGF to the membrane, 
cells were washed with PBS after incubation at 4°C and lysed immediately.  
 
EGF-rhodamine binding and internalisation assay 
PC3 cells were grown on glass coverslips coated with 0.1% w/v gelatine, and were 
transfected with pEGFP-REPS2 using FuGENE, or were used untransfected. The cells 
were treated with 40ng/ml EGF-rhodamine in RPMI with 25mM Hepes for 60 min on ice 
(4ºC), transferred to 37°C and further incubated for 0, 5 or 10 min. Subsequently, the 
 Chapter 3 
54 
cells were fixed with 3% v/v paraformaldehyde and embedded in Vectashield mounting 
medium (Vector laboratories Inc.; Burlingame, CA, USA). An Axioplan 2 fluorescence 
microscope (Carl-Zeiss; Thornwood, NY, USA) was used for analysis. Digital pictures 
were taken with a Coolsnap-pro colour camera (Roper Scientific, BV; Trenton, NJ, 
USA). 
 
Western blotting and Northern blotting 
Western blot analysis was essentially performed as described (Blok et al., 2003).Total 
RNA extraction and Northern blotting was performed as described (Chang et al., 1997). 
Ethidium bromide staining was used to verify equal loading of total RNA.  
 
Results 
 
EGF receptor internalisation and expression in androgen-dependent and 
androgen-independent prostate cancer cell lines 
 
Internalisation of the EGF receptor plays a major role in controlling EGF signalling, 
and EGF signalling may play a role in development of advanced androgen-independent 
prostate cancer. To investigate EGF receptor internalisation, we studied the uptake of 
125I-EGF and expression of the EGF receptor in the androgen-dependent cell line 
LNCaP, in comparison to the androgen-independent cell lines DU145 and PC3. 
It was observed that androgen-dependent LNCaP cells internalise significantly less 
125I-EGF, compared to androgen-independent PC3 and DU145 cells (Figure 3.1A). 
Furthermore, it was also shown that at the start of the experiment, LNCaP cells bound 
significantly less 125I-EGF than the other cell lines, indicating a lower EGF receptor level 
in LNCaP cells than in PC3 and DU145 cells (Figure 3.1A, indicated by the open 
symbols).  
To verify whether decreased binding of 125I-EGF to LNCaP cells (Figure 3.1A, open 
symbols) was the result of decreased EGF receptor expression, Western blotting was 
performed. It was observed that expression of EGF receptor protein in LNCaP cells at 
time point zero was indeed much lower compared to the expression level in PC3 and 
DU145 cells (Figure 3.1B). The non-specific protein band, observed in cell lysates of 
LNCaP cells, just above the EGF receptor protein band, is an unknown protein, which is 
only observed in LNCaP cells. Furthermore, when the three cell lines were cultured in 
the presence of EGF, a rapid (15–45 min) transient increase in EGF receptor 
expression, as observed in PC3 and DU145 cells, was not observed in LNCaP cells. 
Interestingly, a gradual decrease in EGF receptor expression at later time points, 
between 1 and 48h, which is known to be caused by degradation after internalisation 
of the activated receptor, could be observed in all three cell lines (Figure 3.1B). The 
faint extra protein band, appearing in PC3 cells after 2 hours of EGF-treatment, seems 
to increase with longer incubation periods. It is possible that this protein band 
represents the dephosphorylated EGF receptor, because when phosphorylation was 
assessed upon EGF stimulation with an anti-phospho tyrosine antibody, we observed 
an immediate increase of phophorylated forms of the receptor, which decreased after 
45-60 minutes of EGF-treatment (Figure 3.3C).  
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Figure 3.1. Internalisation and expression of EGF receptor in prostate cancer cell lines. 
A.  Internalisation of 125I-EGF was measured in LNCaP, PC3 and DU145 cells at 0, 10 or 45 minutes after 
start of internalisation. After incubation cells were subjected to acid wash and lyses to estimate the 
amount of internalised EGF. The results shown are the mean ± SD of two experiments performed in 
duplicate; each experiment included two independent culture plates. Results are presented as counts per 
minute (cpm), corrected for cell number and background binding. The open circle, square and diamond 
represent total 125I-EGF binding to the cell surface at the start of the experiment.  
B. LNCaP, PC3 and DU145 cells were incubated with 20ng/ml EGF for the indicated times. The amount of 
EGF receptor was determined by Western blot analysis with an anti-EGF receptor antibody. The arrows 
indicate the position of the 170kDa EGF receptor proteins. Equal amounts of protein were loaded on each 
lane, as measured using Bradfords reagent, and verified after electrophoresis by Ponceau S staining. 
 
Involvement of REPS2 in EGF receptor internalisation 
 
REPS2 expression is significantly higher in androgen-dependent prostate cancer cell 
lines (LNCaP) and xenografts, compared to androgen-independent cell lines (PC3 and 
DU145) and xenografts (Chang et al., 1997). To determine whether changed 
expression of REPS2 would affect EGF receptor endocytosis, we transiently transfected 
PC3 cells with a construct encoding GFP-tagged REPS2 and studied endocytosis of 
rhodamine-labelled EGF by fluorescent microscopy, after 24 hours. Cells expressing 
the REPS2-GFP fusion protein bound less ligand and were deficient in EGF-rhodamine 
internalisation (Figure 3.2). These results suggest that over-expression of full-length 
REPS2 has an inhibiting effect on EGF receptor endocytosis and may therefore possibly 
affect subsequent signal transduction. In the above experiment REPS2 was expressed 
as a fusion protein, and the expression level was possibly very high. High expression of 
REPS2 has been shown to induce apoptosis (Oosterhoff et al., 2003). Therefore, a 
more physiological approach was taken next. Using the androgen-independent cell line 
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PC3, which expresses a low level of REPS2 (Oosterhoff et al., 2003), a PC3 subline with 
stable integration of a construct that allows inducible REPS2 expression (PC3-R2) was 
generated. For this gene construct, induction occurs because the activated ecdyson 
receptor dimerizes to the RXR receptor, which turns on expression of the REPS2 gene. 
When these cells were treated with Muristerone A (a ligand for the ecdyson receptor) 
for 24 hours, a higher expression level of the REPS2 protein was detected on Western 
blot (Figure 3.3A). Moreover, this expression level could be further enhanced using the 
synthetic RXR ligand LG268 (kindly provided by Ligand Pharmaceuticals) (Saez et al., 
2000) (Figure 3.3A).  
Figure 3.2. EGF binding and internalisation in cells expressing REPS2-GFP 
PC3 cells were transfected with a construct encoding REPS2-GFP. After 24 hours, the transfected cells 
were incubated with EGF-rhodamine (40ng/ml) for 0, 5 and 10 minutes at 37°C. Cells were fixed and 
analysed by fluorescence microscopy. The upper panel visualizes REPS2-GFP transfected cells, and the 
middle panel shows EGF-rhodamine within the same frame and the lower panel shows the merged 
channels. Cells expressing REPS2-GFP are indicated (magnification: 40x). 
 
The expression level of REPS2 in the inducible cell line (PC3-R2) is comparable to 
the endogenous level in LNCaP cells (Figure 3.3A). Furthermore we have not observed 
or detected loss of cells during 6 days of REPS2-induction, which indicates that there is 
no significant apoptosis-induction in cells with a moderate expression level of REPS2. 
Therefore, these PC3-R2 cells were used for further investigations into the role of 
REPS2 in EGF receptor internalisation and signalling, in relation to the development of 
androgen-independent prostate cancer. 
When EGF receptor internalisation was measured 48 hours after induction of full-
length REPS2 in PC3-R2 cells, an approximate 35% reduction in internalisation of 125I-
EGF was observed (Figure 3.3B). This indicates that REPS2 induction exerts an effect 
on internalisation of the EGF receptor, and/or that REPS2 induction affects EGF 
receptor expression. When total binding of 125I-EGF at the start of the experiment was 
measured, it was observed that in REPS2-induced PC3-R2 cells only 15% less 125I-EGF 
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was bound, compared to non-induced PC3-R2 cells (Figure 3.3B, indicated by the open 
symbols). This result indicates that increased expression of REPS2 does not clearly 
negatively affect EGF receptor expression. To verify this, Western blotting was 
performed. In the absence of any EGF-stimulation, EGF receptor level in induced and 
non-induced PC3-R2 cells was not found to be markedly changed (Figure 3.3C: 0 
min.). 
Figure 3.3. Internalisation and expression of EGF receptor in REPS2 inducible PC3-R2 
cells 
A. Induction of REPS2 expression in PC3-R2 cells. PC3-R2 cells were incubated with Muristerone A (MurA; 
2.5 µg/ml) alone, or in combination with LG268 (100nM) for 24 hours. As a control non-induced cells are 
shown. In a separate experiment, the expression level of REPS2 in PC3-R2 cells is compared to the 
endogenous REPS2 levels in PC3 and LNCaP cells. Expression level of REPS2 was determined by Western 
blot analysis using purified anti-REPS2 polyclonal antibody (Oosterhoff et al., 2003).  Equal amounts of 
protein were loaded on each lane of the gel, as measured using Bradfords reagent, and verified after 
electrophoresis by Ponceau S staining. 
B. Internalisation of 125I-EGF in PC3-R2 cells with (black diamond) or without (black square) induction of 
REPS2 expression. The open diamond and square represent total 125I-EGF binding to the cell surface at the 
start of the experiment. The results shown are the mean ± SD of two experiments with duplicate 
incubation on two independent culture plates. Results are corrected for background binding. 
C. Expression level of EGF receptor in PC3-R2 cells, with (induced) or without (non-induced) induction of 
REPS2. PC3-R2 cells were incubated with 20ng/ml EGF for 0, 10, 20, 30, 45 and 60 minutes. The amount 
of EGF receptor was determined by Western blot analysis with an anti-EGF receptor antibody.  Anti-
phosphorylated tyrosine antibody was used to show fast and transient increase of phosphorylated-tyrosine 
at the same height as the EGF receptor after addition of 20 ng/ml EGF. Equal amounts of protein were 
loaded on each lane of the gel, as measured using Bradfords reagent, and verified after electrophoresis by 
Ponceau S staining. The result is representative for an experiment performed in triplo. 
D. Northern blot analysis of PC3-R2 cells, with or without MurA/LG268 induction of REPS2 expression: 
PC3-R2 cells were incubated with 20ng/ml EGF for 0, 10, 20, 30, 40, 50, 60, 90 and 180 minutes and 24 
hours and total RNA was isolated. Expression of the EGF receptor mRNA was determined using a specific 
cDNA probe. Equal amounts of RNA were loaded on each lane of the gel, as calculated using OD260 
measurements, and verified after electrophoresis by ethidium bromide staining. The result is 
representative for an experiment performed in duplo. 
 Chapter 3 
58 
It was also observed that in non-REPS2-induced PC3-R2 cells expression of EGF 
receptor was initially increased upon culture in the presence of EGF, while in REPS2-
induced PC3-R2 cells EGF stimulation results in a reduction of EGF receptor expression 
(Figure 3.3C). Interestingly, these results are very comparable to the data presented 
in Figure 3.1B for the EGF-stimulated parental PC3 and DU145 cells (both expressing a 
low level of REPS2) in comparison to LNCaP cells (expressing a high level of REPS2). In 
order to verify that indeed the EGF receptor was detected on Western blot, 
phosphorylation at tyrosine residues was measured (for the non-induced situation). 
Because phosphorylation of the EGF receptor itself is an abundant event after EGF 
stimulation, indeed a fast and transient increase in phosphorylated tyrosine was 
observed at the same height as the EGF receptor (Figure 3.3C). To elucidate whether 
inhibition of EGF receptor up-regulation by EGF occurs at the mRNA level, Northern 
blotting was performed. It was observed that induced PC3-R2 cells do not show an 
increased EGF receptor mRNA level as is seen in non-induced cells upon stimulation 
with EGF (Figure 3.3D). These data seem to indicate that induction of expression of 
REPS2 in a cell line, which normally expresses only a low level of REPS2, negatively 
influences EGF-induced EGF receptor expression. Since mRNA and protein expression 
of the EGF receptor gene (in the absence of EGF stimulation) was not affected by 
induction of REPS2 expression (Figure 3.3C and Figure 3.3D, 0 min.) and REPS2 
decreases EGF receptor internalisation (Figure 3.3B), a possible mechanism could be 
that decreased endocytosis results in decreased EGF-signalling to the nucleus. This 
leaves the question whether REPS2 induction would also affect expression of other EGF 
responsive genes. 
 
Involvement of REPS2 in EGF receptor signalling 
 
Since the rate of internalisation of EGF receptor is markedly reduced by REPS2 
induction in PC3-R2 cells, it was investigated whether REPS2 induction would inhibit 
EGF receptor signalling and consequently would have an effect on regulation of mRNA 
expression of a number of EGF-responsive genes. Therefore, the expression of the 
early response genes EGR1, FOS, and JUN, was investigated by Northern blotting. As 
shown in Figure 3.4A, EGR1 expression was transiently up-regulated by EGF, in both 
induced and non-induced PC3-R2 cells. However, the EGR1 mRNA level was already 
decreasing after 40 minutes in the induced cells, whereas in non-induced cells up-
regulation sustained up to 60 minutes after addition of EGF (Figure 3.4A). For FOS 
mRNA expression a very similar observation was made (Figure 3.4B). Interestingly, 
EGF did not regulate the JUN mRNA level, but overall expression of JUN mRNA in the 
induced cells was reduced (Figure 3.4C). As a control for equal loading ethidium 
bromide staining is shown (Figure 3.4D). 
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Figure 3.4. Northern blot analysis of PC3-R2 cells, with or without MurA/LG268 
induction of REPS2 expression 
PC3-R2 cells were incubated with 20ng/ml EGF for the indicated times and total RNA was isolated. 
Expression of the early response genes (A) EGR1, (B) FOS, and (C) JUN was determined using specific 
cDNA probes. Equal amounts of RNA were loaded on each lane of the gel, as calculated using OD260 
measurements, and verified after electrophoresis by ethidium bromide staining (D). The results are 
representative for an experiment performed in duplo. 
 
Discussion 
 
During progression of prostate cancer, growth factors become important regulators 
of cell proliferation (Russell et al., 1998), and growth factor receptor internalisation 
and consequent degradation, control the strength and duration of growth factor-
induced signalling (He et al., 2003). Using cDNA array data from literature 
(Dhanasekaran et al., 2001) we observed that several genes involved in growth factor 
internalisation are down-regulated in metastatic prostate cancer. 
In the present experiments, endocytosis and binding of 125I-EGF was studied in a 
number of androgen-dependent and androgen-independent prostate cancer cell lines. 
The finding that the binding of EGF is relatively high in androgen-independent 
compared to androgen-dependent cell lines, is in agreement with a pronounced role for 
growth factor signalling during hormone-independent prostate cancer growth. In 
addition, we found increased expression of EGF receptors in androgen-independent cell 
lines, which explains the increased EGF binding to these cells. It was suggested 
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previously that EGF-induced endocytosis causes EGF receptor protein degradation in 
prostate cancer cells (Seth et al., 1999) as was shown in B82 Mouse L cells (Wiley et 
al., 1991) and HeLa cells (Vieira et al., 1996). Our experiments show that prostate 
cancer cells internalise 100% of the initially bound ligand within 45 minutes, which can 
explain the observed EGF receptor protein down-regulation after EGF administration. 
Parallel to increased EGF receptor signalling in androgen-independent cell lines, in 
earlier work we found that expression of the endocytosis-related and growth factor 
signalling-involved gene REPS2 was markedly down-regulated (Chang et al., 1997; 
Oosterhoff et al., 2003). In the present experiments the involvement of this protein 
was investigated in relation to the observed changes in EGF signalling during 
androgen-independent prostate cancer growth. When we induced REPS2 expression 
(using an inducible vector system) back to a physiological level in androgen-
independent PC3 cells (PC3-R2 cells), total endocytosis activity was decreased by 
approximately 35%. This reduction in 125I-EGF internalisation may be caused either by 
a decreased EGF receptor expression after EGF-stimulation, or by a direct effect of 
REPS2 on endocytosis. The fact that in the non-REPS2-induced situation the amount of 
125I-EGF, internalised after 45 minutes, does not exceed the initial amount bound to 
the cells at time point 0 minutes, indicates that no extra 125I-EGF is bound in that time 
frame. During the experiment only the initially bound EGF is internalised and at time 
point 0 minutes the expression levels of the EGF receptor are similar between REPS2-
induced and non-induced cells. Therefore, the decrease in 125I-EGF endocytosis is not 
due to the decreased EGF receptor expression after EGF-stimulation. Considering the 
functional domains of REPS2 and the function of its binding partners, a direct role for 
REPS2 in endocytosis-regulation seems more likely.  
The mechanism through which REPS2 reduces ligand-dependent internalisation can 
be explained when we take a number of REPS2 binding partners into account. REPS2 
has been shown to bind to RALBP1, EPA15, Epsin, and indirectly to AP-2 (Kariya et al., 
2000). These proteins complex together and are involved in building the clathrin 
lattice, a dynamic process of association and disassociation of endocytosis-related 
proteins (Pearse et al., 2000). We hypothesise that REPS2 can disturb the dynamics of 
interactions required for an effective assembly of clathrin-coated pits, by recruiting and 
trapping its binding partners RALBP1, EPS15, Epsin and AP-2 in a complex, which 
would inhibit propagation of endocytosis. Additionally, GRB2 has recently been 
implicated in endocytosis regulation (Jiang et al., 2003; Martinu et al., 2002) and since 
REPS2 was reported to bind to GRB2 (Ikeda et al., 1998), this might be another 
candidate involved in endocytosis disruption by REPS2.  
Internalisation of activated EGF receptor is necessary for proper signalling (Ceresa 
and Schmid, 2000) and several effector proteins involved in signal transduction have 
been found to be present in early endosomes (Burke and Wiley, 1999; Jiang and 
Sorkin, 2002; Oksvold et al., 2000; Oksvold et al., 2001). One question, which then 
remained, was whether REPS2-induced changes would indeed translate into changes in 
EGF receptor signalling at the level of expression of EGF-responsive genes. Northern 
blot analysis showed that EGF receptor, EGR1, FOS and JUN mRNAs were either less 
induced by EGF or had lower expression levels in REPS2 expressing cells compared to 
control cells. Although the effect of REPS2 on EGF-induced expression is not severe, 
the fact that it is found on more then one occasion and for four EGF-responsive genes, 
indicates that expression of REPS2 influences EGF receptor signalling in a fairly 
comprehensive manner.  
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Considering that induction of REPS2 expression seems to results in reduced EGF 
receptor endocytosis, that EGF-regulated gene expression is influenced by induction of 
REPS2 expression (present results) and that over-expression of REPS2 in prostate 
cancer cells inhibits growth factor signalling (Oosterhoff et al., 2003), a significant role 
for REPS2 in regulation of EGF signalling seems likely. Reduced REPS2 expression 
during prostate cancer progression may therefore result in increased EGF signalling 
and consequently contribute to carcinogenic properties. 
Down-regulation of REPS2 expression most likely is not the only factor involved in 
increased EGF signalling during advanced prostate cancer development. As presented 
herein, published expression data from different stages of prostate cancer progression 
were evaluated and eight out of fifteen genes involved in endocytosis were found to be 
differentially expressed during prostate cancer progression. This result indicates that 
the process of endocytosis most likely is dysregulated during prostate cancer 
development. Interestingly, it has been described that dysregulated endocytosis can 
lead to mitogenic signalling. Furthermore, mutation or abnormal expression of 
endocytic proteins has been implicated in tumour development (Di Fiore and Gill, 
1999; Floyd and De Camilli, 1998). The present results indicate that further 
investigations into the role of endocytosis during prostate cancer progression will 
improve our understanding of androgen-independent tumour growth. 
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Abstract 
 
Progression of prostate cancer includes molecular and cellular changes leading to a 
transition from androgen-dependent to androgen-independent growth. The initial 
androgen-dependent prostate cancer cells possibly switch from proliferation induced by 
androgens to proliferation that is regulated by growth factors, like epidermal growth 
factor (EGF). EGF and androgens both induce proliferation and invasion in prostate cancer 
cells. With microarray-analysis, contribution of, and overlap between androgen-regulated 
and EGF-regulated genes involved in proliferation and invasion of LNCaP cells, was 
evaluated. Proliferation-related transcripts showed overlap between androgen- and EGF-
regulated genes. However, the majority of genes involved in invasion did not show such 
overlap.  
Upon comparison of the androgen-regulated genes in LNCaP cells with RNA-expression 
data from prostate samples (normal, hyperplasia, cancer, metastases), it was observed 
that a around 50% of these androgen-regulated genes, also present in the prostate 
cancer dataset, were differentially expressed in metastatic prostate cancer samples as 
compared to normal prostate. For EGF-regulated genes, this was less clear, although 
many EGF-regulated invasion-related genes were found to be differentially expressed in 
metastatic prostate cancer as compared to normal prostate.  
These results indicate that EGF and androgens use partly the same pathways to 
control cell proliferation and different pathways to control cell invasion in LNCaP cells. 
Furthermore, the present data support the hypothesis that, although to a lesser extent, 
the EGF-pathway, next to the androgen receptor-pathway, is an important factor in the 
series of events that control prostate cancer progression. 
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Introduction 
 
Androgen ablation therapy for advanced prostate cancer, initially reduces tumor 
growth effectively in over 80% of cases, but usually some cells escape from treatment 
and in due time will lead to appearance of an androgen-independent tumor (Crawford, 
1992). A possible mechanism causing prostate cancer cells to become androgen-
independent involves a switch from steroid hormones to polypeptide growth factors as 
primary regulators of growth. Fibroblast growth factors, insulin-like growth factors, 
transforming growth factors and epidermal growth factor (EGF) are autocrine factors that 
are able to stimulate growth of advanced, androgen-independent, prostate cancer 
(Djakiew, 2000; Russell et al., 1998). Another aspect of androgen-independent prostate 
cancer progression is metastatic outgrowth to other organs like pelvic lymph nodes and 
bone, which is observed in a high percentage of cases. Interestingly, metastatic 
properties of prostate cancer cells can be modulated by androgens (Liao et al., 2003), but 
also by some of the growth factors which are potentially involved in the transition from 
androgen-dependent to androgen-independent prostate cancer growth (Russell et al., 
1998). In particular EGF has been shown to induce both proliferation and invasion of 
prostate cancer cells (Jarrard et al., 1994; Unlu and Leake, 2003). 
The present study has focused on EGF signal transduction, whereby ligand-receptor 
binding induces cell proliferation and invasion by activating well-characterized signal 
transduction pathways that involve phosphorylation and activation of mitogen-activated 
protein kinases (MAPKs). The activation of GTP-ases of the RAS family is one of the initial 
steps in this signal transduction cascade. Once a RAS protein is activated, it can facilitate 
activation of the serine/threonine kinase RAF1, PI3-kinase and RAL-GEF (guanine 
nucleotide exchange factor), which activate the small GTP-ase RALA (Pruitt and Der, 
2001). Activation of many of these signalling molecules induces expression of genes 
through activation of a number of different transcription factors.  
The androgen receptor (AR) also acts as a transcription factor and can be activated by 
MAPK (Craft et al., 1999; Culig et al., 1994). Therefore, there is the possibility of overlap 
and synergy between signalling by androgens and EGF in prostate cancer progression. To 
study transcriptional regulation by EGF in prostate cancer cells we used a comprehensive 
cDNA array for analysis of the expression pattern of a human prostate cancer cell line 
(LNCaP) treated with EGF. To analyse the possible crosstalk between signalling between 
androgens and EGF, we also compared our results with expression profiles of LNCaP cells 
treated with androgens, available from the public domain 
(http://www.cpdr.org/LNCaP/GeneChip/). Furthermore, androgen- and EGF-regulated 
genes were compared to a set of genes differentially expressed in prostate cancer 
progression (Dhanasekaran et al., 2001). It was observed that many genes involved in 
proliferation and invasion were regulated by androgens and/or EGF, and many of these 
genes could be implicated in metastatic prostate cancer progression. The present results 
indicate that in therapies for advanced prostate cancer, both androgen receptor-signalling 
and EGF-signalling should be taken into consideration. 
 
Materials and Methods 
 
Materials and chemicals 
Cell culture flasks and plastic disposables were obtained from Fisher Scientific 
(Houston, TX, USA). RPMI 1640 and culture chemicals were purchased from GIBCO 
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Invitrogen Corporation (Carlsbad, CA, USA). Fetal calf serum (FCS) was from Greiner 
(Frickenhausen, Germany).  
 
Cell culture and EGF treatment 
The LNCaP cells (passage number 22-30), were kindly provided to us by Dr. J.S. 
Horoszewicz (Buffalo, NY). The LNCaP cell line is identical to the one that can be obtained 
from the American Type Culture Collection (Rockville, MD). LNCaP cells were maintained 
at 37°C in a humidified incubator containing 5% CO2/95% air in RPMI 1640 supplemented 
with 200 IU/ml penicillin, 200 µg/ml streptomycin and 5% v/v fetal calf serum (FCS). 
Before EGF treatment, LNCaP cells were cultured for 48 h in medium containing 5% v/v 
dextran coated charcoal-treated FCS (DCC-FCS) and then treated with additional added 
EGF (20 ng/ml) for various periods of time. Media were refreshed every two days. Total 
RNA was extracted by lysing the cells with 3 M lithium chloride/6 M urea (Chang et al., 
1997).  
 
DNA microarray hybridisations and data analysis 
DNA microarrays consisting of amplified cDNAs from Incyte's Human LifeSeq® 
Foundation printed on glass slides were used in these studies (Agilent, Palo Alto, CA, 
USA). Each array contained cDNAs representing over 14,000 unique human genes and 
expressed sequence tags (ESTs). For each hybridisation, 13 µg of total RNA was used in a 
direct labelling protocol. The RNAs of the different time points were all hybridised on 
separate arrays, with RNA of untreated cells as reference sample. Labelling, hybridisation, 
scanning procedures and data compiling was performed by ServiceXS, Leiden, The 
Netherlands (http://www.servicexs.com/), with Agilents G2566AA Feature Extraction 
Software. The compiled experimental data were further analysed using Microsofts Excel 
program. 
Spots of which the mean signal corrected for the mean background was less than 3 
times higher than the standard deviation (SD) of the background were flagged and 
excluded from analysis. This calculation excluded spots with low intensity, compared to 
the background intensity, as well as spots with low spot quality, determined by SD of the 
background. Additionally, spots of which the mean signal was less then two-fold higher 
than the mean background were also excluded from analysis. 
Gene annotation was determined with OMIMTM (Online Mendelian Inheritance in ManTM) 
and LocusLink (NCBI) at http://www.ncbi.nlm.nih.gov/. Hierarchical and K-means 
clustering was performed at http://ep.ebi.ac.uk/EP/EPCLUST/. 
 
Growth studies 
LNCaP cells were maintained in RPMI 1640 medium containing 5% FCS. One day prior 
to plating, the cells were transferred to medium containing 5% DCC-FCS. The cells were 
passaged to 24-well plates, at 5000 cells per well and treated with epidermal growth 
factor (EGF) for the indicated lengths of time at a concentration of 20 ng/ml. Media were 
refreshed every two days. 16 h prior to harvest, the cells were incubated with 9.25 KBq 
3H-thymidine (specific activity 46 Ci/mMol). Subsequently, the cells were washed twice in 
PBS and lysed in 1ml NaOH for 1 h at 37°C. 3H-Thymidine incorporation was measured in 
0.5 ml lysate diluted in 4.5 ml scintillation fluid using a 2500TR scintillation analyser 
(Packard Bioscience BV, Groningen, The Netherlands). Standard deviations were 
calculated from quadruplicate incubations within one representative experiment.  
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Invasion assay 
After culture in RPMI containing 5% FCS, LNCaP cells were detached with trypsin and 
seeded in the upper well of a modified Boyden chamber (Transwell, 6.5 mm inserts, 8 µm 
pores; Corning Costar, Cambridge, MA, USA) at 5x104 cells/well in 100µl medium, with or 
without 20 ng/ml EGF and/or 0.1 nM R1881. In the lower well, 600 µl 5% DCC-FCS-
supplemented medium with or without EGF and/or R1881 was loaded. After 72 hours of 
culturing, the number of cells that had migrated through the filter into the lower well were 
counted in triplicate. EGF treatment was also varied in time. Cells were cultured in a 
modified Boyden chamber for 6 days with or without added EGF as indicated in the 
legends to the figures. Media were refreshed every two days. The experiments were 
performed in triplicate, and were repeated 3 times. 
 
Results 
 
Androgen and EGF stimulate growth and invasion of LNCaP cells 
Both normal prostate cells as well as prostate cancer cells depend, during most 
stages of oncogenic progression, on androgens for growth and maintenance. The 
presently used LNCaP cell line is a human prostate cancer cell line which is derived from a 
lymph node metastasis (Horoszewicz et al., 1980). Not only are LNCaP cells dependent on 
androgens for their growth, but they also respond to EGF (Guo et al., 2000; Schuurmans 
et al., 1991). To verify that the LNCaP cell line used in our laboratory showed the same 
growth characteristics as described in literature, the growth-response to either androgens 
or EGF was determined by 3H-thymidine incorporation assay. 
Figure 4.1. Proliferation induction by EGF and/or R1881 treatment of LNCaP cells 
LNCaP cells were treated for the indicated times with 20 ng/ml EGF and/or 0.1 nM R1881. Media were 
refreshed every two days. Proliferation rates after 7 days of culturing were determined measuring 3H-
thymidine incorporation during the last 16 hours. Differences between control and treated samples were 
statistically significant with a paired-samples t test (* P≤ 0.008, # P ≤ 0.055). 
 
EGF (20 ng/ml) was found to induce cell growth in LNCaP cells within 2 days and this 
effect reached maximum stimulation after 3 days (Figure 4.1).  Stimulation of cell growth 
by the synthetic androgen R1881 (0.1 nM) was observed after 2 days and reached its 
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maximum after 4 days of treatment. Administration of both EGF and R1881 together had 
an additive effect on cell growth (Figure 4.1). This indicates that androgens and growth 
factors utilize different signalling pathways, as was suggested previously (Guo et al., 
2000). Because LNCaP cells respond to EGF and R1881, these cells provide us with a 
model to study molecular mechanisms involved in stimulation of prostate cancer cell 
growth by EGF compared to stimulation of growth by androgens. 
An important risk during prostate cancer progression, next to androgen-independent 
growth, is migration and invasion of prostate cancer cells to nearby and more distant 
tissues and organs. EGF has been reported to stimulate invasion of prostate cancer cells 
in vitro (Jarrard et al., 1994). To confirm stimulation of invasion of LNCaP cells by EGF, 
we studied the invasive capacity of LNCaP cells after addition of EGF, using the Boyden 
chamber micro-invasion assay. As expected, an increase in invasion after EGF treatment 
was observed (Figure 4.2A). Interestingly, when cells were incubated only the last day in 
medium containing added EGF we measured a 4-fold increase in invasion over the control 
situation (Figure 4.2A; 5-/1+).  
Figure 4.2. Invasion stimulation by EGF and/or R1881 treatment of LNCaP cells 
A. LNCaP cells were treated with 20 ng/ml EGF for 1, 3 or 6 days, when EGF was added after 5, 3 or 0 
days of culture respectively (* P< 0.04). Media were refreshed every two days. Invasion was 
determined by counting the cells that had passed across a Boyden chamber membrane. Results are 
presented as % of the originally seeded cell number. 
B. LNCaP cells were treated with 20 ng/ml EGF and/or 0.1 nM R1881 for 3 days, and the number of cells 
that had migrated across the membrane was counted and presented as % of the originally seeded cell 
number. (* P< 0.03) 
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When the cells were cultured for a total of 3 days (Fig 2A; 3-/3+) or 6 days (Fig 2A; 0-
/6+) in the presence of EGF, only a 2-fold increase in invasion was observed between 
days 1 and 3, and no further increase between days 3 and 6. Proliferation of migrated 
cells in the lower well may contribute to this effect, but it is also possible that stimulation 
of invasion is initiated during the first 24 hours in the presence of added EGF, and needs 
more time to take effect.  
To address possible crosstalk between R1881 and EGF stimulated pathways, the effect 
of R1881 on invasion of LNCaP cells was also studied. LNCaP cells were treated with 
R1881 (0.1 nM) and/or EGF (20 ng/ml) for 3 days, and thereafter invasion was assessed. 
Both hormones were found to stimulate the cells to migrate through the transwell. 
Furthermore an additive effect was observed when both hormones were administered 
together (Figure 4.2B). 
 
Androgen- and EGF-regulated genes involved in stimulation of growth and 
invasion of LNCaP cells 
 
LNCaP cells were passaged, grown on medium containing 5% charcoal-stripped serum 
for 2 days and subsequently stimulated with EGF (20 ng/ml) for 0, 1.5, 24, 72 and 144 
hours. Total RNA was isolated and hybridised to a micro-array containing approximately 
14,000 human cDNAs (Agilent). The data were normalized as indicated in Materials and 
Methods.  
Expression levels changed more than two-fold in response to EGF stimulation in 380 
(2.7%) of the transcripts after 1.5 hours, in 1544 (10.8%) after 24 hours, in 95 (0.7%) 
after 72 hours and in 166 (1.1%) after 144 hours of EGF treatment. To check whether the 
generated expression profiles were relevant, we examined the regulation of 9 previously 
reported EGF-regulated genes in prostate cancer cells.  
 
Table 4.1. Transcription regulation of 9 genes in prostate cancer cells after EGF-treatment, 
according to literature and the present analysis using cDNA arrays 
 
Spots of which the mean signal corrected for the mean background was less than 3 times higher than the 
standard deviation (SD) of the background were flagged. Fold change is indicated with – when down-
regulated and + when up-regulated. (Blok et al., 1995; Guillemette et al., 1997; Henttu and Vihko, 1993; Mizokami et al., 
1992; Perry et al., 1998; Tsai et al., 2000; Ye et al., 1999) 
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The transient and early genes, EGR1, TIEG, FOS, JUN and CCND1 showed an increased 
expression on the micro-array until 24 hours. Of the genes that were reported to be 
down-regulated, only UDP-glycosyltransferase responded clearly in accordance with 
literature. CDKN1B (P27KIP1), kallikrein 3, and the androgen receptor (AR) were reported 
to be down-regulated by EGF, but this was not always the case for all micro-array data 
(Table 4.1). 
Both EGF and R1881 induce cell growth (Figure 4.1) and invasion (Figure 4.2) in 
LNCaP cells. EGF and androgens may exert such effects by regulating the same genes 
and/or different genes. To determine the correlation between EGF-regulated genes and 
R1881-regulated genes we searched literature for sources of androgen-regulated genes in 
LNCaP cells. DePrimo et al. (2002) published a transcriptional analysis of R1881-regulated 
genes in LNCaP cells (DePrimo et al., 2002). Xu et al. (2001) and Clegg et al. (2002) 
prepared expression profiles of androgen responsive transcripts in LNCaP cells by serial 
analysis of gene expression (SAGE) (Clegg et al., 2002; Xu et al., 2001). Additionally, 
Segawa et al. (2002) evaluated androgen regulated genes in LNCaP cells using Affimetrix 
oligonucleotide arrays (Segawa et al., 2002). Segawa et al. (2002) used the 
concentration of R1881 (0.1 nM) that has been found to induce maximum growth 
(Schuurmans et al., 1988a; Taneja et al., 2001), which is also the concentration used in 
the present experiments. Therefore, the data set of Segawa et al. (2002) was compared 
to the presently identified EGF-regulated genes. The time-series used in the two 
experiments were different: in the EGF-experiment, array-analysis was performed after 
1.5, 24, 72 and 144 hours, while for the R1881-experiment, 1, 6, 12 and 24 hours of 
incubation was chosen. However, since the number of genes that was regulated by EGF 
only after either 72 or 144 hours was low (10 genes), this was assessed not to be a 
problem. 
K-means clustering is a method that recognizes and visualizes regulatory patterns in 
sets of genes. To do so, the data are partitioned in a user defined K number of groups 
around the mean of all data-points. To optimally visualize the results, K-means clustering 
with 4 clusters was performed on genes regulated at least 2-fold in 1 data-point by both 
EGF and R1881 (Figure 4.3). 224 genes were found to be regulated by EGF and R1881, 
44% in the same direction (co-regulated, either up or down) and 56% in the opposite 
direction (contra-regulated, either up/down or down/up). Clusters 3 and 4 show contra-
regulated genes, cluster 2 contains genes that are co-regulated (mainly up-regulated) by 
both EGF and R1881, and cluster 1 contains a more diverse group with low expression 
levels (Fig 4.3A). 
Using OMIMTM (Online Mendelian Inheritance in ManTM) and LocusLink (NCBI), genes 
involved in invasion (including cell motility and cell adhesion; n=37) and genes involved 
in proliferation (including growth, apoptosis or oncogenes; n=48) were identified, and 
distribution of these genes in the earlier defined four clusters was indicated (Figure 4.3B). 
It was observed that clusters 3 and 4 contain a high percentage of genes involved in 
invasion, while genes involved in proliferation were mainly found in clusters 2 and 3 (Fig 
4.3B). Interestingly, most genes involved in proliferation were present in cluster 2, 
containing genes that are mainly up-regulated by EGF and R1881, which indicates that 
the effect of EGF and androgens on cell growth is partly through stimulation of 
transcription of the same genes.  
Since the majority of genes (68%) involved in invasion were contra-regulated (Figure 
4.3A; clusters 3 and 4), regulation of invasion by EGF and R1881 seems to result mainly 
from stimulation or repression of different genes. 
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Figure 4.3. K-means clustering analysis compares EGF- or R1881- induced gene expression in LNCaP 
cells  
A. K-means clustering, using Euclidian distance measurements, of EGF-regulated transcripts and R1881-
regulated transcripts (Segawa et al., 2002). K=4, cut-off is shown at 2-fold change.  
B. Genes involved in invasion or proliferation (growth, oncogenes) as % of total number of genes present 
in cluster 1, 2, 3 or 4. 
 
Evaluation of a possible involvement of R1881- and EGF-regulated genes in 
progression of prostate cancer 
 
Both androgen- and EGF-signalling play a role in prostate cancer progression. 
Therefore, the present cell line data on EGF and the additional cell line data on androgens 
obtained from literature, were compared to a large gene expression data set containing 
normal prostate samples, next to benign hyperplasia, prostate cancer and hormone-
refractory prostate cancer metastatic samples (Dhanasekaran et al., 2001).  
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Figure 4.4. Hierarchical cluster analysis, to compare gene expression in LNCaP cells and different 
prostate samples 
This analysis uses correlation based distance measurements and complete linkage of gene expression in 
prostate cancer samples (Dhanasekaran et al., 2001) compared with genes regulated by either EGF or R1881 
(Segawa et al., 2002) in LNCaP cells. NAP: normal adjacent prostate, BPH: benign prostate hyperplasia, PCA: 
prostate cancer, MET: metastasis. Each row represents a single transcript, each column an experiment and 
red and green represent up- and down-regulation respectively (see scale). 
A. Clusters 1 and 2: compared with genes regulated by EGF in LNCaP cells  
B. Clusters 3, 4 and 5: compared with genes regulated by R1881 in LNCaP cells (Segawa et al., 2002). 
C. Genes (clusters 1-5 of Figure 4A and B) regulated by EGF or R1881 presented as % of the number of 
genes co-regulated or contra-regulated compared to their expression in metastasis (MET). 
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First, hierarchical clustering of genes up- or down-regulated at least two-fold in one 
time point in our EGF dataset and also present in the prostate expression dataset was 
performed. Results are shown as cluster diagrams, each row represents a single 
transcript, each column an experiment and red and green represent up- and down-
regulation respectively. As shown in Figure 4.4, two metastasis restricted clusters were 
generated (Figure 4.4A; clusters 1 and 2). 
These gene clusters were identified as metastasis restricted, based on different 
expression levels in the metastasis group as compared to the other prostate cancer 
samples. Genes in cluster 1, e.g. are mainly down-regulated (green) in the metastasis 
samples as compared to the other prostate samples (red). A similar evaluation was 
performed for genes that were up- or down-regulated by androgens at least two-fold in 
one time point in the dataset from Segawa et al. (2002) and present in the prostate 
cancer expression data set from Dhanasekaran et al., (2001). As shown in Figure 4.4B, 
three other clusters could now be identified. Expression levels of genes present in clusters 
3 and 5 (and 1 and 2) were metastasis restricted, while expression levels of genes 
present in cluster 4 were generally prostate cancer specific. 
Genes in clusters 1 and 2 were all down-regulated in prostate cancer metastasis as 
compared to their expression level in normal and cancer samples, but only 27% of these 
genes were also down-regulated by EGF (Figure 4.4C; upper open bar). This suggests 
that many EGF target genes are not important in metastatic progression. In contrast, 
from the genes present in clusters 3, 4 or 5, 57% was co-regulated by androgens (Figure 
4.4C, lower open bar), indicating that androgen target genes play a much more significant 
role in hormone–refractory metastasis. 
To this point, the present results show that clusters that discriminate metastatic 
prostate cancers from other prostate samples can be found within EGF- or androgen-
regulated genes. However, since we are interested in crosstalk between androgen- and 
EGF-signalling pathways, cluster analysis on genes regulated by both EGF and R1881 and 
present in the Dhanasekaran et al. (2001) dataset was performed. The overlap between 
the used datasets involves only 83 genes and is too small to draw conclusions about the 
importance of crosstalk between EGF and androgen signalling for prostate cancer 
progression.  
Of these 83 genes, 39 genes showed differential expression in metastasis samples as 
compared to normal and BPH samples (Fig 4.5; clusters 6, 7 and 8). Cluster 6 contains 
genes that are differentially expressed in prostate cancer and metastasis, while clusters 7 
and 8 are differentially expressed only in metastasis. In the three indicated clusters, a 
weak correlation was observed between EGF and androgen target genes and their 
expression in prostate cancer progression: 16 genes (34%) are regulated in the same 
direction by EGF, androgens and in prostate cancer progression (Table 4.2).  
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Figure 4.5. Hierarchical cluster analysis, to compare gene expression in LNCaP cells and different 
prostate samples 
This analysis uses correlation based distance measurements and complete linkage, of gene expression in 
prostate cancer samples compared with genes regulated by EGF and R1881 in LNCaP cells. . Each row 
represents a single transcript, each column an experiment and red and green represent up- and down-
regulation respectively (see scale). 
Clusters 6, 7 and 8 are differentially expressed in metastasis (MET) or prostate cancer (PCA) compared to 
normal prostate (NAP) and benign hyperplasia (BPH) and regulated by EGF and R1881. 
 
Table 4.2 Genes that are regulated in the same direction by EGF, androgens and in prostate cancer 
metastasis 
 
 
Name and function of genes that are regulated in the same direction by EGF, androgens and in prostate 
cancer metastasis. Whether transcripts are present twice (2x) on the microarray is indicated. 
Similar to rat HREV107 (2x) 
Solute carrier family 4, anion exchanger, member 2  
Envoplakin 
Calcium (ca2+) homeostasis endoplasmic reticulum 
protein 
Galactose-4-epimerase  
SREBP CLEAVAGE-ACTIVATING PROTEIN 
Translocase of outer mitochondrial membrane 34 (2x)
Activated leucocyte cell adhesion molecule 
Transcription elongation factor A (SII)-like 1 
RAB6, member RAS oncogene family (2x) 
Ste20-related serine/threonine kinase 
High-mobility group protein 17-like 3 
Phospholipase A2, group IIA 
Genes down-regulated by EGF, androgens and in metastasis
Genes up-regulated by EGF, androgens and in metastasis
Unknown 
Oxidative stress  
Cytoskeleton 
Calcium homeostasis  
 
Carbohydrate metabolism 
Lipid metabolism  
Mitochondrial translocation
Cell adhesion 
Negative regulation of transcription 
Intracellular protein transport 
Apoptosis; actin stress fiber dissolution 
Enhanced transcription  
Membrane lipid catabolism  
NAME 
NAME 
FUNCTION
FUNCTION
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Discussion 
 
In the present experiments, administration of both EGF and R1881 simultaneously was 
found to have an additive effect on cell growth and invasion of LNCaP cells. This indicates 
that androgens and growth factors utilize divergent signalling pathways in these cells, as 
was suggested previously by Guo et al. (Guo et al., 2000). However, there are also 
several reports on crosstalk between androgen- and EGF-signalling in the prostate. 
Schuurmans et al. (1988b) reported that R1881 induces EGF receptor expression, while 
Mizokami et al. (1992) found that EGF down-regulates androgen receptor (AR) mRNA 
expression in LNCaP cells (Mizokami et al., 1992; Schuurmans et al., 1988b). 
Furthermore, there is also evidence that EGF stimulates AR activity via the MAPK pathway 
(Craft et al., 1999; Culig et al., 1994), but proliferation of LNCaP cells induced by 
androgens was not found to be mediated by activation of MAPK (ERK1/2) (Bell et al., 
2003). Another possible level at which crosstalk between androgen- and EGF-signalling 
can take effect is by regulation of the same genes. For example, both androgens and EGF 
inhibit expression of CDKN1B and stimulate expression of CDK2 (Ye et al., 1999), thus 
inducing proliferation. Although many observations do point towards an important role for 
both signalling pathways in regulation of prostate cancer growth, the interaction between 
AR- and EGF receptor-mediated pathways is still not fully understood. Since we found 
additive stimulation of both invasion and cell proliferation by androgens and EGF, 
crosstalk between these hormones was investigated further with microarray-analysis. 
Upon comparison of the present cDNA array data on EGF stimulation of LNCaP cells 
with data from literature on R1881 stimulation of the same cell line (Segawa et al., 2002), 
a considerable overlap in regulation of genes involved in proliferation was observed. This 
indicates that some crosstalk between EGF- and androgen-signalling exists at this level. 
For regulation of genes involved in invasion, however, this was much less evident; EGF 
and R1881 regulated only 32% of the invasion-related genes in the same direction, up or 
down. It seems logical that androgen- or EGF-regulation of these proliferation- or 
invasion-involved genes results in changed proliferation or invasion, but individual genes, 
or groups of genes should be studied in detail in order to confirm their involvement.  
When we compared genes differentially expressed in hormone refractory metastasis 
samples (as compared to normal or tumor samples of prostate cancer patients) with the 
EGF- and R1881-regulated genes, we found that 43% of the genes regulated by EGF and 
41% of the genes regulated by R1881 were metastasis-specific. These figures are high, 
but only a quarter of the EGF-regulated genes are co-regulated when compared to their 
expression in metastasis, while for R1881-regulated genes this is more than 50%. These 
data suggest that in hormone-refractory metastasis, the EGF signalling pathway might be 
hardly activated, while the androgen receptor signalling pathway still seems to play a 
significant role.  
The androgen receptor-signalling pathway is still largely active in androgen-
independent prostate cancer cells, as has been suggested before. For example, it has 
been observed that some genes that are differentially expressed in hormone refractory 
xenografts compared to androgen-dependent xenografts, are still androgen-responsive 
(Amler et al., 2000; Mousses et al., 2002). However, whether activation of the AR in an 
androgen-deprived environment is achieved through autocrine stimulation by growth 
factors, as has been suggested by others (Feldman and Feldman, 2001; Grossmann et 
al., 2001), can not be extracted from the present data. A possible way to investigate this, 
would be to compare androgenic signalling in hormone-dependent prostate cancer cells 
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with EGF signalling in androgen-independent prostate cancer cells. These investigations 
are currently being conducted. 
Recently, it has been reported that stimulation of AR transactivation in advanced 
prostate cancer cells by EGF requires an already partly activated AR (Gregory et al., 
2003). Since we used EGF to stimulate LNCaP cells in the absence of added androgens, 
and the AR is therefore expected to be largely or completely inactive in these cells, 
activation of AR-regulated pathways and co-regulated genes should not be found. In 
correspondence with this, it was observed that most EGF- and R1881-regulated genes 
were contra-regulated, either in LNCaP cells or in metastasis, although 43% was still co-
regulated.  
A major draw back of comparison of two microarray datasets of different experiments, 
is loss of data due to the use of different chips. The overlap between androgen-regulated 
genes from Segawa et al., 2002, and the microarray used for the EGF experiment is only 
40%. Furthermore, when the EGF- and androgen-regulated sets of genes were compared 
with the set of hormone refractory prostate metastasis-specific genes, the overlap 
between the three datasets was found to be very low (n = 83), so that no relevant 
conclusions could be drawn.  
In summary, LNCaP cells are stimulated by EGF and androgens to proliferate and to 
migrate. Addition of both these hormones together showed additive effects. Analysis of 
gene expression profiles indicates that additive proliferation induction is partly achieved 
by induction of the same genes, while stimulation of invasion by EGF and androgen is 
mainly achieved via different signalling pathways. Additionally, gene-expression analyses 
indicated that androgen target genes are still activated in hormone-refractory metastatic 
prostate cancer samples and therefore offer potential targets for intervention. For EGF-
regulated genes, this was less clear, although many of the genes, which were found to be 
regulated by EGF and differentially expressed in metastatic prostate cancer, are thought 
to be involved in invasion.  
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Abstract 
 
Prostate cancer development often includes a shift from androgen-dependent 
towards androgen-independent growth. It is hypothesized that, during this transition, 
growth factors like the epidermal growth factor (EGF) gain importance as activators of 
cell proliferation. To study the differences between androgen-dependent and 
androgen-independent cells, androgen- and EGF-regulation of growth and gene-
expression was analysed in the androgen-dependent human prostate cancer cell line 
LNCaP-FGC (FGC) and its androgen-independent derivative line LNCaP-LNO (LNO).  
It was observed that androgen-dependent FGC cells require exposure to either 
androgens or EGF to proliferate. This is in contrast to androgen-independent LNO cells 
that showed significant proliferation in medium depleted of androgens and growth 
factors. Gene expression data were obtained for the androgen-dependent FGC and 
androgen-independent LNO cells cultured in the presence or absence of androgens 
(synthetic R1881) or EGF for different time periods. Expression profiling showed that 
many cell cycle genes including a number of androgen- and EGF-regulated genes were 
constitutively activated in androgen-independent LNO cells. Furthermore, the overlap 
between changes in gene expression activated by androgen and EGF receptor 
signalling pathways was found to be very high (75%). These results partly explain why 
androgen-independent LNO cells can proliferate in the absence of androgenic 
stimulation.  
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Introduction 
 
Molecular mechanisms involved in the transition from androgen-dependent to 
androgen-independent prostate tumour growth have been subject of research for 
many years. Candidate mechanisms involving the androgen receptor (AR) have been 
suggested, including mutations that activate AR transcriptional activity, over-
expression of co-activators of the AR, and crosstalk with other growth signalling 
pathways (Balk, 2002; Shaffer and Scher, 2003). The focus of the present study is on 
androgen crosstalk with the epidermal growth factor (EGF), next to changes in gene-
expression and gene-regulation, during progression of prostate cancer.  
Peptide growth factors are, next to androgens, essential for prostate growth and 
maintenance of prostate function (Russell et al., 1998). In normal prostate, peptide 
growth factors act in a paracrine manner: stroma cells produce growth factors which 
act on epithelial cells (Hayward et al., 1997). In prostate cancer, production of growth 
factors switches to an autocrine mode, where epithelial cells become stimulated to 
produce their own growth factors (Wong and Wang, 2000). In addition, growth factor 
signalling during prostate cancer progression is enhanced because the expression 
levels of several important growth factor receptors increase. 
Djakiew (2000) and Russel (1998) extensively reviewed the involvement of many 
growth factors and their receptors in prostate cancer (Djakiew, 2000; Russell et al., 
1998). The EGF receptor has been reported to be expressed at higher level in 
malignant prostate tissue, compared to normal prostate (Di Lorenzo et al., 2002; 
Scher et al., 1995). However, other investigators reported no change or even a 
decrease in EGF receptor expression (Robertson et al., 1994; Turkeri et al., 1994). 
Possible regulation of EGF and its receptor by androgens is also subject of discussion. 
In normal prostate, androgens stimulate expression of EGF in stromal cells (Hiramatsu 
et al., 1988; Nishi et al., 1996), but in prostate cancer cells this is not observed 
(Connolly and Rose, 1990; Russell et al., 1998). Furthermore, it is not clear whether 
androgenic control of EGF receptor expression involves increased or decreased 
expression (Di Lorenzo et al., 2002; Djakiew, 2000; Fiorelli et al., 1991; Schuurmans 
et al., 1988). Still, a detailed analysis of the changing pattern of expression of EGF and 
the EGF receptor during progression of prostate cancer did indicate that a switch from 
paracrine to autocrine EGF signalling can play a role in autonomous growth of 
androgen-independent prostate cancer cells (Scher et al., 1995).  
The intracellular domain of the EGF receptor is a tyrosine kinase, which, upon 
ligand binding of the receptor, becomes activated to form a docking site for several 
cytoplasmic adaptor proteins (Wells, 1999; Yarden, 2001). These adaptors sequester 
proteins that stimulate different kinase cascades such as the MAP kinase cascade. As a 
result, newly phosphorylated proteins may directly affect cell growth, differentiation 
and migration, independent of transcriptional regulation, or may activate transcription 
factors, that induce expression of genes which play a role in these processes (Garbay 
et al., 2000; Yarden, 2001). The AR is a transcription factor, which is activated by 
androgens and then translocates to the nucleus where the receptor-ligand complex 
regulates transcription of many genes involved in growth and maintenance of the 
normal prostate (Balk, 2002; Gelmann, 2002). In androgen-independent prostate 
cancer, the AR has been suggested to be activated by other substances then 
androgens (Grossmann et al., 2001). Since activation of the AR may involve 
phosphorylation (Brinkmann et al., 1999; Gelmann, 2002) and the EGF signalling 
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pathway activates MAP kinases, EGF-induced and androgen-independent activation of 
the AR seems a possibility. In fact, activation of the AR via MAP kinases by EGF, and 
also through HER2, another EGF receptor, has been reported (Culig et al., 1994; 
Gregory et al., 2003; Yeh et al., 1999).  
The human prostate cancer cell line LNCaP-FGC (FGC) is a model for androgen-
dependent growth. In the current study we show that this cell line indeed depends on 
androgen or EGF action for its growth. An important derivative of this cell line is the 
androgen-independent LNCaP-LNO (LNO) cell line, which was developed from cultures 
of an early passage of LNCaP-FGC (Chang et al., 1997; Horoszewicz et al., 1980; van 
Steenbrugge et al., 1991). Using microarray-analysis, these androgen-dependent FGC 
and androgen-independent LNO cell lines were investigated, to establish the 
differences between these cell lines on gene-expression and gene-regulation. 
Furthermore to determine to what extent androgenic- and EGF-signalling become 
intertwined during the transition from androgen-dependent to androgen-independent 
prostate cancer growth. Constitutive activation of cell cycle genes in androgen-
independent cells was observed, next to an increase of overlap between androgen- and 
EGF-induced genes.  
 
Materials and Methods 
 
Materials and chemicals 
Cell culture flasks and plastic disposables were obtained from Fisher Scientific 
(Houston, TX, USA). RPMI 1640 and culture chemicals were purchased from GIBCO 
Invitrogen Corporation (Carlsbad, CA, USA). Fetal calf serum (FCS) was from Greiner 
(Frickenhausen, Germany), EGF from SIGMA-Aldrich Chemie BV (St. Louis, MI). R1881 
(methyltrienolone) was purchased from NEN (Boston, MA), AG1478 from Calbiochem 
(San Diego, CA). Bicalutamide (ICI176.334, casodex) was from AstraZeneca 
(Macclesfield, UK), and was dissolved freshly in ethanol prior to use. 
 
Cell culture and  treatment 
The LNCaP-FGC cells (FGC, passage number 22-30) were kindly provided to us by 
Dr. J.S. Horoszewicz (Buffalo, NY). Identical cells can be obtained from the American 
Type Culture Collection (Rockville, MD). FGC cells were maintained in RPMI 1640 
supplemented with 200 IU/ml penicillin, 200 µg/ml streptomycin and 5% v/v fetal calf 
serum (FCS) at 37°C in a humidified incubator containing 5% CO2/95% air. The LNO 
cell line has been derived from an early passage (6th) of the parental FGC cell line 
(Horoszewicz et al., 1980). These cells were grown under the same conditions as their 
parental cells, except that the serum used was DCC-FCS, depleted of steroids by 
dextran-coated-charcoal treatment using 0.1% dextran and 1% charcoal (van 
Steenbrugge et al., 1991).  
Before EGF or androgen treatment, LNCaP cells were cultured for 48 h culture in 
medium containing 5% v/v DCC-FCS and then treated with additional added EGF (20 
ng/ml) or R1881 (0.1 nM) for various periods. Total RNA was extracted by lysing the 
cells with 3 M lithium chloride/6 M urea (Chang et al., 1997).  
 
Micro-array analysis 
DNA microarrays consisting of amplified cDNAs from Incyte's Human LifeSeq® 
Foundation printed on glass slides were used in these studies (Agilent, Palo Alto, CA ). 
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Each array contained over 14,000 unique human genes and expressed sequence tags 
(ESTs). For each hybridization, 13 µg of total RNA was used in a direct labeling 
protocol. The RNAs of the different time points were all hybridized on separate arrays, 
with RNA of untreated cells as reference sample. Labeling, hybridization, scanning 
procedures and data compiling was performed by ServiceXS, Leiden, The Netherlands 
(http://www.servicexs.com/), with Agilents G2566AA Feature Extraction Software. The 
compiled experimental data were further analysed using Microsoft’s Excel program and 
Rosetta Resolver Gene Expression Data Analysis System (Rosetta Inpharmatics LLC). 
Gene annotations were done with GO-MAPPER, a locally developed annotation tool 
(Smid and Dorssers, 2004). Cluster-analysis was performed with Expression Profile 
data CLUSTering and analysis (EPCLUST) at http://ep.ebi.ac.uk/EP/EPCLUST/. 
 
Cell growth study 
FGC and LNO cells were grown for three days in DCC-FCS and then plated in 24 
well plates (4⋅104 cells/ml). Three days after plating, test media were administered 
with 20ng/ml EGF, 0.1 nM R1881, 3 mM Casodex  and 300 nM AG1478. Another three 
days later, these media were refreshed, and after 6 days of incubation cells were lysed 
in 1 M NaOH, and OD 260 was determined. 
 
Results 
 
Androgen-dependent (FGC) and androgen-independent (LNO) human LNCaP 
prostate cancer cell lines were treated with the synthetic androgen R1881 (0.1 nM) or 
EGF (20 ng/ml) for 0, 1.5, 12, 24 or 72 hours in medium depleted of steroids (5% v/v 
DCC-FCS). After treatment, total RNA was isolated and gene expression was measured 
using comprehensive oligoarrays. Using the Rosetta Resolver Gene Expression Data 
Analysis System (Rosetta Inpharmatics LLC) and the Microsoft®Excel program 
(Microsoft Corporation), up- or down-regulated genes were identified. Genes with a p-
value of ≤ 0.05 and a changed expression of at least 2-fold in at least one data point, 
were defined as regulated. Because the oligoarray data obtained with RNA isolated 
after 12h of treatment of FGC cells with EGF was of poor quality, inconsistent data 
from this array were left out from the analysis.  
 
Differences in gene expression between androgen-dependent and androgen-
independent LNCaP cell lines under non-hormone-stimulated conditions  
 
Androgen-dependent FGC and androgen-independent LNO cell lines originate from 
the same patient-sample and the same genetic background (van Steenbrugge et al., 
1991). These cell lines represent a model, where FGC cells need androgens or growth 
factors or both to proliferate (are androgen-dependent), whereas LNO cells have 
progressed and proliferate without further hormonal substitutions (are androgen-
independent). This cellular difference leads to at least two questions. First, since 
androgen-independent LNO cells do not require added androgens or EGF for growth, to 
what extent are the associated signal transduction pathways constitutively activated? 
Second, do differentially expressed cell cycle genes play a role in androgen-
independent growth of LNO cells? 
To assess constitutive differences between the two cell lines, all non-hormone-
stimulated data from androgen-dependent FGC cells were compared to all non-
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hormone-stimulated data from androgen-independent LNO cells. In practice, this 
implies that the average of all Cy5-data for over 17,000 genes on the arrays were 
compared for each cell line. Transcripts for which the SD was higher then 25% of the 
average were excluded from this analysis. To verify the quality of collected data, to be 
able to compare the cell lines, several tests were conducted. The average Cy5 signals 
in FGC cells and in LNO cells showed a normal distribution, and signal intensities of 
positive and negative controls on the arrays were no more that 1.4-fold different. 
Furthermore, known differentially expressed genes like TRPS1 and REPS2 (Chang et 
al., 1997), TMEFF2 (Gery et al., 2002), vimentin (Singh et al., 2003), CDC2 (Kallakury 
et al., 1999), IGFBP2 (Bubendorf et al., 1999) and the AR (Balk, 2002) were indeed 
detected as differentially expressed between the two cell lines (not shown).  
It was observed that 1350 genes out of 6702 expressed genes that met the 
restrictions were differentially expressed between the two non-hormone-stimulated cell 
lines; in androgen-independent LNO cells 848 transcripts were expressed higher and 
502 transcripts were expressed lower, as compared to androgen-dependent FGC cells 
(Figure 5.1). Because LNO cells proliferate when cultured under non-hormone-
stimulated circumstances and the androgen-dependent FGC cells are then largely 
inhibited in growth, it is expected that this growth difference will be reflected in the 
profiles of gene expression. 
To determine whether androgen- or EGF-regulated pathways are constitutively 
activated, potential androgen or EGF target genes were compared with the cohort of 
differentially expressed genes in the non-hormone stimulated situation. Androgen or 
EGF target genes were defined as genes with a changed expression of at least 2-fold in 
at least one data point after EGF or androgen exposure of FGC cells. Approximately 
21% (181 out of 848) of the genes with a 2-fold higher expression in LNO cells (Figure 
5.1A, grey area) were found to be up-regulated by R1881, or EGF, or both in FGC 
cells. Of the genes with a 2-fold lower expression in LNO cells compared to FGC (Figure 
5.1A, white area) approximately 14% (70 out of 502) were also down-regulated by 
R1881 or EGF or both in FGC cells (Figure 5.1A). It is suggested that approximately 
20% of the identified differentially expressed genes are differentially expressed 
because androgen- and EGF-signalling is constitutively activated in LNO cells (Figure 
5.1A). Therefore, the capacity of androgen-independent cells to proliferate without 
androgenic stimulation, might be caused in part by constitutive activation of androgen- 
and EGF-signalling. 
Next, to assess a possible role of differentially expressed cell cycle genes, the 
known functions of all genes that were differentially expressed between non-hormone-
stimulated cell lines were determined using the annotation tool GO-MAPPER that was 
developed by Smid and Dorssers (2004) (Smid and Dorssers, 2004). This program 
categorizes genes into the different levels of the gene-ontology hierarchy 
(http://www.geneontology.org/doc/GO.doc.html). From the annotated genes (606 
could be annotated) that were higher expressed in LNO cells, 31% were categorized in 
“cell growth and maintenance” (of which 15% in “cell proliferation”), 59% in 
“metabolism” and 10% in “cell communication”. Genes with a 2-fold lower expression 
in LNO cells were also categorized, and the result displayed more genes in “cell 
communication” (26%) and less in “cell proliferation” (5%).   
In total 105 “proliferation-annotated” genes (Figure 5.1B) were differentially 
expressed between androgen-dependent FGC and androgen-independent LNO cell 
lines. Interestingly, 29 of the differentially expressed genes appeared to be androgen- 
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or EGF-regulated (Figure 5.1B). These results further strengthen the hypothesis that 
androgen-independent cells may partly regulate proliferation by constitutive activation 
of androgen- or EGF-signalling pathways or both. 
 
Figure 5.1. Differential gene expression between androgen-dependent (FGC) and androgen- 
independent (LNO) LNCaP cell lines  
A. Number of genes differentially expressed between androgen-independent (LNO) and androgen-
dependent (FGC) cells.  Androgen (R1881) and EGF target genes are indicated within these differential 
genes. 848 genes are at least 2-fold higher expressed in LNO cells as compared to FGC cells. 502 genes 
are at least 2-fold lower expressed in LNO cells as compared to FGC cells.  
B. Number of differentially expressed genes between LNO and FGC cells involved in proliferation. 
Androgen (R1881) and EGF target genes are indicated within these proliferation genes. 90 proliferation-
involved genes are at least 2-fold higher expressed in LNO cells as compared to FGC cells. 15 
proliferation-involved genes are at least 2-fold lower expressed in LNO cells as compared to FGC cells.  
The filled segments represent transcripts that are higher expressed in LNO compared to FGC cells 
(LNO>FGC), and the open segments represent transcripts that are lower expressed in LNO cells compared 
to FGC cells (LNO<FGC). 
 
Androgen- and EGF-regulated genes in androgen-dependent and androgen-
independent LNCaP cell lines  
 
Androgen-dependent FGC cells need steroid hormones or growth factors to 
proliferate, whereas androgen-independent LNO cells proliferate through endogenous 
stimulation of growth. Comparison and analysis of androgen- and EGF-regulated genes 
in both cell lines provides information to what extent signal transduction pathways 
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converge to stimulate growth in androgen-dependent FGC cells and androgen-
independent LNO cells.  
It was observed that there is much overlap between androgen- and EGF-regulated 
genes in both cell lines. In androgen-dependent FGC cells, at least 40% of the genes 
that are regulated by R1881 are also regulated by EGF (Figure 5.2; Table 5.1), 
indicating that R1881 and EGF stimulate partly the same cellular processes. Most 
(97%) of these overlapping genes are regulated in the same direction, either up or 
down (Table 5.1). In LNO cells the overlap between R1881 and EGF up-regulated 
genes is much larger, although the absolute numbers are in the same range as for FGC 
cells (Figure 5.2; Table 5.1). Almost 75% of androgen up-regulated genes in LNO cells 
are also EGF up-regulated in these cells. This may indicate that in androgen-
independent LNO cells EGF receptor signalling has made androgenic signalling partly 
redundant. Therefore, instead of androgens, locally produced EGF may act as a 
primary mitogen for LNO cells. 
Figure 5.2. Number of identified androgen- and EGF-regulated genes in androgen-dependent 
FGC and androgen-independent LNO cell lines  
The number of androgen-regulated transcripts is presented in white and EGF-regulated genes in grey. The 
number of genes regulated by both are shown in the overlapping fragments and are indicated in italics. 
The upper two pictures show up-regulated genes, the lower two down-regulated genes. Genes regulated 
in FGC cells are on the left, genes regulated in LNO cells are on the right. 
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Table 5.1. Number of genes up- or down-regulated by R1881 or EGF or both in FGC or LNO cells 
or both.  
  
 
The number of genes regulated at least two-fold with a p-value ≤ 0.05 in at least one time point by 
androgen (R1881) or EGF or both, in FGC cells or LNO cells or both. 
 
To assess this hypothesis in a biological setting, proliferation assays were 
performed. FGC and LNO cells were cultured in the presence or absence of R1881, 
EGF, and/or specific inhibitors of AR action (Bicalutamide) or EGF receptor signalling 
(AG1478) for 6 days. Bicalutamide is an anti-androgen that inhibits the transcriptional 
activity of the AR in LNCaP cells (Veldscholte et al., 1992). AG1478 is a highly specific 
inhibitor of the EGF receptor that attenuates EGF signalling in LNCaP cells (Guo et al., 
2000). It was observed that androgen-dependent FGC cells showed a very low 
proliferation rate during the time frame of the experiment in the non-hormone-
stimulated situation, while the androgen-independent LNO cells showed a 6-fold 
increase in cell growth. Furthermore, upon culture of FGC cells in the presence of 
R1881 or EGF, cell growth was increased by 3-fold or 2.2-fold, respectively. When both 
compounds were added together, an additive effect was observed (4.4-fold), indicating 
indeed separate pathway usage by androgens and EGF in the androgen-dependent 
FGC cell line. In contrast to these observations, R1881 had only a minor effect on 
growth of LNO cells (Figure 5.3; 1.4-fold on average), while EGF supplementation, 
alone or in combination with R1881, had no effect on growth of these cells. 
If stimulation of growth by the two hormones (either separate or combined) was 
restrained by specific inhibitors (Bicalutamide or AG1478), it was observed that these 
compounds act as expected in androgen-dependent FGC cells. In androgen-
independent LNO cells, however, the antiandrogen Bicalutamide inhibits only androgen 
signalling, while hardly no effect was observed of the EGF receptor inhibitor AG1478 
(Figure 5.3). So, despite the fact that many proliferation-annotated genes are 
regulated by androgens and EGF and are higher expressed in the androgen-
independent LNO cell line, inhibition of EGF signalling at receptor level hardly affects 
growth of this cell line. Therefore, it is hypothesized that, in androgen-independent 
LNO cells, parts of the proliferation machinery are constitutively activated through 
mutations, deletions or amplifications of key genes acting downstream from the 
androgen or EGF receptors, or through autonomous activation of other signalling 
pathways.  
up up up up down down down down
FGC R1881 FGC EGF LNO R1881 LNO EGF FGC R1881 FGC EGF LNO R1881 LNO EGF
703 333 235 210
923 381 379 11
596 426 1 1
517 1 0 0
431 156 23 5
8 450 28 8
1 4 91 9
1 0 0 14
up FGC R1881
up FGC EGF
up LNO R1881
up LNO EGF
down FGC R1881
down FGC EGF
down LNO R1881
down LNO EGF
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Figure 5.3. Regulation of growth of androgen-dependent FGC and androgen-independent LNO 
cells by androgen (R1881), EGF, Bicalutamide and AG1478 
Cells were incubated with 20ng/ml EGF, 0.1 nM R1881, 3 mM Bicalutamide and 300 nM AG1478 in the 
indicated combinations. After 6 days cells were harvested in 1N NaOH and OD260 values were measured 
in diluted samples. Growth is expressed as a percentage of the OD260 value at the start of the 
incubations. The experiments were conducted in 24 well plates; each measurement is the average of four 
wells +/- SD. Results shown are representative of an experiment performed three times. All control 
incubations were performed in the presence of vehicle (0.1% ethanol) 
 
Interestingly, in the prostate cancer cell lines described herein, we found 56 genes 
involved in PI3Kinase pathway signalling to be differentially expressed between the 
two lines in the non-hormone-stimulated situation. Of these 56 differential genes, 7 
were androgen- or EGF-regulated. Another 29 genes were androgen- or EGF-
regulated, but not differentially expressed (Figure 5.4). The PI3Kinase pathway is 
involved in prostate cancer progression and is essential for survival of LNCaP cells in 
an androgen-deprived environment (Lin et al., 1999). Therefore, regulation and 
expression differences of the PI3Kinase pathway between FGC and LNO cells were 
assessed by screening phosphorylated AKT kinase expression in these cells after 
stimulation by EGF or androgen. It was observed that AKT kinase was highly 
phosphorylated in both cell lines in the present non-hormone stimulated situation, but 
expression of phosphorylated AKT in FGC was twice as high as its expression in LNO. 
Addition of either R1881 or EGF had no effect on activation or expression levels of AKT 
kinase in both cell lines (data not shown). This indicates that the PI3Kinase pathway is 
constitutively activated in both cell lines, and is therefore not responsible for the 
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proliferative advantage of androgen-independent prostate cancer cells over androgen-
dependent prostate cancer cells.  
 
Figure 5.4. Transcriptional regulation of genes involved in PI3Kinase signalling 
Hierarchical clustering with uncentered distance measure, of all PI3Kinase-involved transcripts that are 
regulated either by androgen (R1881) or EGF at least two-fold and in at least one time point, or are 
differentially expressed between FGC and LNO. Whether the transcripts are regulated (white boxes), 
differentially expressed (yellow boxes) or both (blue boxes), is indicated on the right. Samples analysed 
are represented by columns, and shown from left to right are: FGC cells, treated with R1881 (0.1 nM) for 
1.5, 12, 24 or 72 hours; FGC cells treated with EGF (20 ng/ml) for 1.5, 24 or 72 hours; LNO cells treated 
with R1881 (0.1 nM) for 1.5, 12, 24 or 72 hours; LNO cells treated with EGF (20 ng/ml) for 1.5, 12, 24 or 
72 hours. Each row represents a single transcript and red and green represent up- and down-regulation, 
respectively (see scale).  
 
Hierarchical clustering of genes, differentially regulated between androgen-
dependent and androgen-independent LNCaP cell lines 
 
So far, differences between androgen-dependent FGC and androgen-independent 
LNO cell lines in a non-hormone-stimulated situation, and the overlap between 
androgen and EGF signalling for these two cell lines, was analysed. As a subsequent 
step, we aimed to identify regulated genes that may contribute to functional 
differences between the two cell lines.  
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First, all genes that were regulated in at least one of the arrays were analysed 
using hierarchical clustering at http://ep.ebi.ac.uk/EP/EPCLUST/ (Figure 5.5). Some 
highly androgen- or EGF-regulated genes and their positions in the clusters are 
depicted (Figure 5.5). The black bars to the left of the figure indicate clusters for which 
gene regulation in LNO cells is clearly different from gene regulation in FGC cells. 
Because we are interested in these gene clusters, ANOVA analysis was used to 
calculate which regulated genes were indeed differentially regulated between FGC and 
LNO cells.  
 
Figure 5.5. Transcriptional program activated by R1881 or EGF in FGC or LNO cells  
Hierarchical clustering with uncentered distance measure, of all transcripts that are regulated either by 
androgen (R1881) or EGF at least two-fold and in at least one time point. Samples analysed are 
represented by columns, and shown from left to right are: FGC cells treated with R1881 (0.1 nM) for 1.5, 
12, 24 or 72 hours; FGC cells treated with EGF (20 ng/ml) for 1.5, 24 or 72 hours; LNO cells treated with 
R1881 (0.1 nM) for 1.5, 12, 24 or 72 hours; LNO cells treated with EGF (20 ng/ml) for 1.5, 12, 24 or 72 
hours. Each row represents a single transcript, and red and green represent up- and down-regulation 
respectively (see scale). Black bars on the left indicate regions with differential gene expression 
signatures. Enlarged sections on the right indicate representative androgen- or EGF-regulated genes. 
Genes indicated with an asterisk have previously been reported as androgen- or EGF-regulated genes. 
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Using the Rosetta Resolver Gene Expression Data Analysis System, 1138 genes 
were identified which were significantly differentially regulated between FGC and LNO 
(at least 2-fold and at least in one time point, by either EGF or androgen; p-
value<0.05) (Figure 5.6A). Within this dataset, two distinct clusters were formed that 
were either up-regulated in androgen-independent LNO cells and not regulated in 
androgen-dependent FGC cells (cluster A) or vice versa (cluster B). All transcripts, and 
transcripts specifically present in the two clusters were annotated using GO-MAPPER 
(Smid and Dorssers, 2004) to a cellular function as indicated in Figure 5.6B. 
Interestingly, it was observed that cluster B contains more transcripts involved in 
proliferation and transport and less transcripts involved in transcription and 
communication as compared to cluster A.  
 
 
Figure 5.6. Differential transcription activation by androgen (R1881) or EGF in FGC or LNO cells  
A. Hierarchical clustering with uncentered distance measure, of all transcripts that are either regulated 
by androgen (R1881) or EGF at least two-fold in at least one time point and are differentially 
regulated between FGC and LNO as determined by Anova analysis with Rossetta Resolver, P<0.05. 
Indicated cluster A contains transcripts that are up-regulated in LNO cells but not regulated in FGC 
cells by androgen and/or EGF. Cluster B contains transcripts that are not regulated in LNO cells but 
up-regulated in FGC cells by androgen and/or EGF.  
B. Annotation of all genes differentially regulated or present in cluster A or B as % of annotated genes 
in these groups. Annotation was performed using GO-MAPPER (Smid and Dorssers, 2004). 
 
This suggests that cluster B contains genes that play a role in cell cycle control. To 
verify this, genes that were identified by Whitfield et al. (2002), which showed periodic 
variation during the cell cycle in HeLa cells (Whitfield et al., 2002) were compared to 
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the EGF- or androgen-regulated genes from Figure 5.6A. 202 genes were found to 
overlap between the Whitfield data set (containing 1134 genes) and our 1138 
regulated genes (Figure 5.7). Of these 202 overlapping genes, 77 were present within 
cluster B. This number is remarkably high and indicates that cluster B indeed contains 
a subgroup of genes that may play a role in cell cycle control. Furthermore, since 
regulation by androgens and EGF of genes included in cluster B is very distinct 
between FGC and LNO cell lines, it is hypothesized that at least parts of the 
mechanisms that control the cell cycle are differentially regulated in androgen-
dependent cells as compared to androgen-independent cells.  
Figure 5.7. Analysis of transcripts periodically expressed in the cell cycle and regulated by 
androgen or EGF in FGC or LNO  
Hierarchical clustering with uncentered distance measure, of transcripts present in the Thy-Thy3 (0-46 
hours) cell cycle experiment described by Whitfield et al. (Whitfield et al., 2002) and the present LNCaP 
experiment. Samples analysed are represented by columns, and shown from left to right are: HeLa cells, 
sampled each hour until 46 hours after synchronized release from cell cycle arrest; FGC cells treated with 
R1881 (0.1 nM) for 1.5, 12, 24 or 72 hours; FGC cells treated with EGF (20 ng/ml) for 1.5, 24 or 72 
hours; LNO cells treated with R1881 (0.1 nM) for 1.5, 12, 24 or 72 hours; LNO cells treated with EGF (20 
ng/ml) for 1.5, 12, 24 or 72 hours. The regions indicated by black bars contain genes that are up-
regulated in FGC and not regulated in LNO cells. The white bar indicates a small region representing genes 
for which this regulation is in a reverse manner. 
 
Discussion 
 
Androgen-independent prostate cancer growth is the endpoint of tumour 
development, from normal growth of prostate cells that is induced and regulated by 
androgens to aberrant growth that is induced and maintained by other factors and 
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mechanisms. These factors and mechanisms include sensitization of the androgen 
receptor and activation of other signalling pathways, like cytokine and growth factor 
signalling or oncogenic signalling (Balk, 2002; Grossmann et al., 2001).  
The human prostate cancer cell line LNCaP-FGC (FGC) is a model for androgen-
dependent growth. In the current investigation, we show that this cell line depends on 
either androgen or EGF for its growth. In contrast, growth of the LNCaP-LNO (LNO) cell 
line, an androgen-independent sub-line of FGC is not dependent on androgen or EGF, 
and influenced only to a minor extent by exposure to these hormonal factors. 
As a model for transition from androgen-dependent to androgen-independent 
prostate cancer growth, the above-mentioned two cell lines were explored. To identify 
differences between androgen-dependent and -independent growth, gene expression 
profiling was performed. Expression of both androgen and EGF receptors was 
approximately twice as high in FGC as compared to LNO cells, as determined by 
Western blotting (not shown). Because many genes were activated by androgen and 
EGF in the androgen-independent LNO cell line, it was concluded that receptor 
expression levels were sufficient to generate a response. Various analyses of the 
results were executed yielding information about differential signal transduction 
pathway usage by the two cell lines. 
Using the averages of the intensities of the reference samples, that represented a 
non-hormone-stimulated situation, a group of genes was defined that is differentially 
expressed between the androgen-dependent and the androgen-independent cell lines. 
This group includes a large number of androgen- and EGF-regulated and/or 
proliferation-related genes. Possibly, constitutive activation of these specific clusters of 
genes in the androgen-independent cell line adds to the autonomous growth behavior. 
The observations that the androgen-independent cells grew well on steroid hormone-
free medium, and that addition of R1881 or EGF, or addition of an anti-androgen or 
EGF receptor-inhibitor, had little effect on this growth, further indicated the presence 
of a constitutive activated proliferation pathway. Furthermore, it is interesting to note 
that in LNO cells, the absolute number of EGF-regulated genes involved in proliferation 
is remarkably lower as compared to the number in FGC cells (29 in LNO, 67 in FGC).  
Upon analysis of genes that were differentially regulated by R1881 or EGF or both, 
it was observed that the overlap between EGF and R1881 activated genes is 
approximately 75%. In the androgen-dependent FGC cells, this number is much lower, 
since only 40% of EGF and androgen activated genes overlap. Whether the EGF 
receptor pathway and the AR pathway in androgen-independent LNO cells indeed show 
more crosstalk then in FGC, could not be confirmed, since LNO cells hardly respond to 
specific anti-androgen (Bicalutamide) and EGF receptor signal inhibitor (AG1478). This 
last observation, however, could indicate that the proliferation machinery is 
constitutively activated through mutations, deletions or amplifications of key 
regulatory genes acting down-stream from the androgen or EGF receptors, or through 
activation of other signalling pathways.  
A potential candidate pathway to induce proliferation in androgen-independent cells 
is the PI3Kinase pathway. It has previously been reported that, in LNCaP cells, the 
PI3Kinase pathway is constitutively active (Pfeil et al., 2004) and essential for survival 
in an androgen-deprived environment (Lin et al., 1999). It was observed that 
androgen-ablation increased the activity of PI3Kinase and AKT during establishment of 
androgen-independent sublines of LNCaP, and that addition of androgens blocked that 
effect (Murillo et al., 2001). It should also be mentioned, however that other reports 
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do not described such a difference in expression of PI3Kinase and AKT after long-term 
androgen ablation of FGC cells (Pfeil et al., 2004).  
In the present study, it was observed that 56 PI3Kinase-annotated genes were 
differentially expressed between FGC and LNO cells and 36 PI3Kinase-annotated genes 
were androgen- or EGF-regulated (of which 7 genes are both differentially expressed 
and hormone-regulated). However, when we measured activity of PI3Kinase by 
measuring phosphorylated AKT, constitutive activation of the PI3Kinase pathway in 
both cell lines was found, with the highest activity in FGC and no effect of either 
androgen or EGF addition. Constitutive active PI3Kinase could be an important 
determinant which prevents FGC cells from dying during androgen ablation, but the 
lower activity of the PI3Kinase pathway in LNO cells cannot explain the proliferative 
advantage of the androgen-independent cells. Therefore other proliferation-inducing 
pathways must be activated in these cells.  
Cluster-analysis of regulated genes resulted in formation of groups of genes that 
showed differential regulation between FGC and LNO cells. Two groups were extremely 
different, either up-regulated by EGF and/or androgens in LNO and not regulated by 
EGF and/or androgens in FGC, or vice versa. A remarkably high number of genes 
involved in proliferation was found in the group that was up-regulated in FGC and not 
regulated in LNO cells. Furthermore, when compared to previously identified genes 
regulated during the cell cycle in HeLa cells (Whitfield et al., 2002), 77 cyclic genes 
were found to be up-regulated in FGC and not regulated in LNO.  Up-regulation of 
these cell cycle regulated genes specifically in FGC could indicate that this 
asynchronous cell population contains many cycling cells after addition of androgens 
and/or EGF. If this is the case, then LNO cells should express many cell cycle regulated 
genes without addition of androgens or EGF, since these cells grow well under those 
circumstances. Indeed 138 genes from the Whitfield data-set were higher expressed in 
LNO as compared to FGC in the non-hormone-stimulated situation. Furthermore, 33 
out of these 138 transcripts were implicated in cancer, which also indicates that LNO 
cells possess a phenotype associated with proliferative tumour cells. Recently an 
interesting comparison was made between LNCaP cells inhibited in growth by 
methylseleninic acid (MSA) and periodically expressed cell cycle genes (Whitfield et al., 
2002). Most cell cycle-involved genes (74%) were found to be down-regulated in 
LNCaP cells that were inhibited in growth (Zhao et al., 2004). We found 60% of the cell 
cycle regulated genes to be up-regulated in LNCaP-FGC cells that were stimulated in 
growth by either R1881 or EGF. 
Validation of differentially expressed or regulated genes will be required. However, 
several genes previously reported and shown to be differentially expressed between 
FGC and LNO cells were confirmed with these microarray experiments. B-cell 
translocation gene 1 as well as REPS2 and TRPS1 were determined by RNA differential 
display (25) and also by these microarray-analyses to be differentially expressed 
between FGC and LNO cells. Furthermore, EGF- or androgen-regulated genes like 
EGR1, TIEG, FOS, PSA and AR were previously reported (40-42) and confirmed here 
(Fig. 5). 
In summary, it is suggested that androgen-independent LNO cells can proliferate in 
the absence of androgenic stimulation, because: first, many cell cycle genes including 
a number of androgen- and EGF-regulated genes are constitutively activated; second, 
the overlap between androgen receptor signalling and EGF receptor signalling 
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pathways is very high (80%); third, other unknown signal transduction pathways have 
been activated and induce proliferation.  
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General Discussion  
 
 
Prostate cancer in its early stages is an endocrine-controlled cancer, but, while it 
progresses, the cancer switches from androgen-dependent to -independent growth. 
The organ and early cancerous lesions that develop from it both need androgens for 
development, maintenance and growth. However, when the cancer progresses, it 
survives and grows without androgens. A significant portion of prostate cancer 
research focuses on mechanisms behind the transition from androgen-dependent to 
androgen-independent growth, to eventually find possible targets for intervention 
(Chapter 1). The experiments described in this thesis focus on two aspects of 
androgen-independent prostate cancer growth: 
1. The protein REPS2, which is lost from androgen-independent prostate cancer and 
plays a role in EGF receptor signalling (Chapters 2 and 3) 
2. EGF receptor signalling as a potential alternative proliferation- and invasion-
inducing pathway during androgen-independent prostate cancer growth (Chapters 4 
and 5). 
 
 
6.1 REPS2 
 
REPS2 was originally identified by our laboratory as a protein encoded by a 
transcript with high expression in androgen-dependent and low expression in 
androgen-independent human prostate cancer cell lines and xenografts (Chang et al., 
1997). As indicated in Table 1, others confirmed this finding when comparing gene 
expression in normal prostate with that in advanced prostate cancer. Because of the 
potential role of REPS2 in development of androgen-independent prostate cancer, for 
the experiments described in Chapters 2 and 3 the following question was posed:  
 Via which mechanisms does loss of expression of the endocytosis protein REPS2 
contribute to an androgen-independent phenotype of prostate cancer cells? 
 
6.1.1 REPS2 induces apoptosis 
 
As described in Chapter 2, overexpression of REPS2 induces apoptosis of prostate 
cancer cells and inhibits transcription from an EGF responsive reporter construct. It 
was hypothesized that REPS2 acts via binding to RALBP1 and consequently via 
inactivation of RAC1 and CDC42 signalling. RALBP1 functions mainly as a CDC42 Gap 
protein (Cantor et al., 1995). CDC42 has been implicated in cell cycle control via 
stimulation of E2F-mediated transcription, possibly by inducing Cyclin D1 expression 
(Gjoerup et al., 1998). CDC42-induced expression of Cyclin E and Cyclin A (Chou et 
al., 2003; Philips et al., 2000) has also been described, linking CDC42 activity directly 
to progression through the G1 phase of the cell cycle. Inhibition of CDC42, by RALBP1 
via overexpression of REPS2, could therefore lead to inhibition of the cell cycle.  
Whether increased REPS2 expression indeed leads to inhibition of the cell cycle or 
has a more general inhibiting effect on cell survival, however, remains to be 
elucidated. Identification of the p65 subunit of the cell survival protein complex NF-κB 
as a binding partner of REPS2 raised a new possible explanation for the observed 
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induction of apoptosis by REPS2 (Penninkhof et al., 2004). In a series of experiments, 
Penninkhof et al. (2004) described specific binding of p65 to the EH domain of REPS2, 
but did not find a physiologic response. In our report Oosterhoff et al. (2003) (Chapter 
2) we described induction of cell death in cells transiently expressing REPS2-GFP 
(Oosterhoff et al., 2003). However, this effect was only seen in cells with a fairly high 
expression of RESP2-GFP. Since over-expression of proteins can lead to artificial 
effects, a stable cell line with a moderate, more physiological level of REPS2-
expression was generated (described in Chapter 3). Upon testing these cells, increased 
apoptosis could not be detected. Therefore, we measured proliferation, but no 
significant decrease in cell number by induced REPS2 expression was observed. 
Apparently, more subtle ways of measuring cellular changes are required for 
observations on possible effects of physiological changes in the expression level of 
REPS2.  
 
6.1.2 REPS2 inhibits growth factor signalling 
 
Transient transfection with wild-type REPS2 showed decreased transcription from 
an EGF-responsive reporter-construct (Chapter 2). The experiments described in 
Chapter 3 were performed with a physiological level of REPS2 expression and also 
showed decreased EGF signalling. The mechanism, hypothesized in Chapter 3, 
concerns REPS2-induced inhibition of EGF signalling through inhibition of EGF receptor 
endocytosis. Interestingly, EGF receptor endocytosis was shown to be inhibited by both 
over-expression of REPS2-GFP (Chapter 2) and moderate expression of wild-type 
REPS2 (Chapter 3).  
Again, the ability of REPS2 to bind RALBP1 and consequently to inactivate CDC42 
could explain the observed effect. Both proteins have been described to be involved in 
growth factor endocytosis: RALBP1 as part of a complex with AP-2 (Jullien-Flores et 
al., 2000), and CDC42 by binding to ACK2, a kinase which, when activated, binds to 
the clathrin heavy chain (Erickson and Cerione, 2001). Additionally, Epsin and Eps15, 
two endocytosis-involved binding partners of REPS2 (Morinaka et al., 1999; Torrisi et 
al., 1999), could also play a role in inhibition of endocytosis by REPS2.  
From the experiments using a physiological expression level of REPS2, it was also 
clear that the observed effects of REPS2 induction were reproducible but not very 
pronounced. It was therefore of interest to find that the expression of many other 
proteins involved in endocytosis becomes down-regulated during development of 
prostate cancer metastasis (Dhanasekaran et al., 2001). 
  
6.1.3 REPS2 as target gene in prostate cancer progression 
 
Taken together, results regarding apoptosis induction of REPS2 in prostate cancer 
cells should be interpreted with caution, but the effect on growth factor signalling and 
growth factor receptor endocytosis seem to be of importance. Loss of REPS2 
expression in androgen-independent prostate cancer and consequently loss of control 
over growth factor signalling, either directly or via inhibition of endocytosis of activated 
receptors, is hypothesized to lead to a more malignant phenotype.  
Differential expression of genes, for example between androgen-dependent and 
androgen-independent prostate cancer, is nowadays determined by the use of 
microarrays. A practical data mining tool that enables researchers to efficiently quarry 
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genes and datasets of publicly available cancer microarray studies, is the Oncomine 
Infrastructure (Rhodes et al., 2004). Using this tool, all microarray data available to 
the public domain from normal human prostate or prostate cancer were examined for 
the expression of REPS2. The results are summarized in Table 6.1.  
 
Table 6.1: Mean expression level of REPS2 in different prostate cancer samples as investigated 
by the indicated first authors  
 
 
 
Mean expression levels of REPS2 in the indicated prostate samples. Gleason scores indicate stages of 
prostate cancer, high scores correlate with more advanced stages. The gene is considered to be up-
regulated (red) if the mean expression level of sample 1 is lower then the mean expression level of 
sample 2, and down-regulated (green) if the mean expression level of sample 1 is higher then the mean 
expression level of sample 2. The p value is a measure of significance of the difference between the two 
tissue samples provided by the Oncomine website (*p value≤ 0.02). For more information on data 
calculation: www.oncomine.org and (Rhodes et al., 2004).  
 
Compared to normal prostate tissue, REPS2 expression is up-regulated (red) in 
prostate cancer samples. However, REPS2 expression is down-regulated (green) in 
prostate cancer with an aggressive, most likely androgen-independent, phenotype. 
These results, although not all significant, correspond with our data on REPS2 
expression in androgen-independent cells as compared to androgen-dependent cells, 
described in Chapter 2.  
One report (Henshall et al., 2003), not mentioned in the table, studied 72 prostate 
cancer samples and determined the correlation between REPS2 gene expression and 
PSA relapse of the patient. PSA relapse is generally accepted as indicative for relapse 
of the disease after surgery or during hormone treatment. Decreased expression of 
REPS2 was found to be strongly correlated with relapse of the PSA level measured in 
blood of the patients (Henshall et al., 2003). It was calculated that patients with a 
lower expression of REPS2 have an approximate 6-fold increased risk of relapse, which 
indicates that REPS2 may serve as a prognostic indicator. 
Study Name Sample 1 Sample 2 Mean 1 Mean 2 P Value
LaTulippe (2002) Normal Prostate (n=3) Prostate Cancer (n=23) -0.14 0.09 0.27 
LaTulippe (2002) Prostate Cancer (n=23) Metastatic Prostate Cancer (n=9) 0.09 0.02 0.81 
LuoJH (2002) Normal Prostate (n=15) Prostate Cancer (n=15) -0.07 0.20 0.01* 
Singh (2002) 
No PSA recurrence at 3 years 
(n=31) 
PSA Recurrence at 3 years (n=8) -0.02 -0.06 0.86 
Singh (2002) Nontumor Prostate (n=48) Prostate Cancer (n=52) -0.08 -0.01 0.46 
Singh (2002) Prostate Cancer: Gleason 6 (n=15) 
Prostate Cancer: Gleason 8,9 
(n=4) 
0.05 -0.43 0.02* 
Welsh (2001) Normal Prostate (n=9) Prostate Cancer (n=25) -0.84 0.03 0.00* 
Welsh (2001) Prostate Cancer: Gleason 6 (n=8) 
Prostate Cancer: Gleason 8,9 
(n=7) 
-0.05 -0.09 0.84 
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6.2 EGF receptor signalling in androgen-dependent and –independent 
prostate cancer cells 
 
To determine in more detail which signalling pathways are affected in prostate 
cancer progression, microarray analysis were performed. Because the EGF pathway 
has been described to be involved in prostate cancer progression (Russell et al., 1998), 
in Chapter 4 the following questions were asked: 
 Is it possible to identify genes, activated by androgens or EGF, that induce 
proliferation and invasion of prostrate cancer cells? 
 Do EGF- and androgen-signalling overlap in prostate cancer cells and if so, to 
what extent? 
 
6.2.1 Regulation of proliferation and migration 
 
Androgen-independent prostate cancer cells use different mechanisms to grow 
under circumstances where androgen availability is low. One possible mechanism for 
prostate cancer cells to overcome androgen ablation is to switch from androgens to 
growth factors, like EGF, for regulation of growth (Djakiew, 2000; Russell et al., 1998). 
Besides changed growth characteristics, advanced prostate cancer also displays a high 
metastatic potential: of all prostate cancer patients, approximately one third develop 
metastasic lesions outside the prostate, mainly in the pelvic bone. It is thought that 
both androgens and EGF stimulate the metastatic potential of prostate cancer. 
In the androgen-dependent prostate cancer cell line LNCaP proliferation and 
invasion are both enhanced by androgens (Liao et al., 2003; Schuurmans et al., 1991) 
and EGF (Jarrard et al., 1994; Unlu and Leake, 2003). Because we were interested in 
the transcriptional aspects of these processes in prostate cancer, this cell line was used 
to study the regulatory effects of androgens and EGF on genes involved in modulation 
of proliferation and invasion. 
Significant effects of androgens and EGF on proliferation and migration rates of 
LNCaP cells are shown in Chapter 4. Using microarray analysis on LNCaP cells treated 
with EGF (our own data), and microarray data of LNCaP cells treated with R1881 
(Segawa et al., 2002), the genetic response in LNCaP cells to androgens and EGF was 
examined. Of the genes that were regulated by androgens (Segawa et al., 2002) or 
EGF, approximately 25% was found to be involved in cell growth and maintenance, 
and almost half of these genes was classified to be involved in proliferation regulation. 
Interestingly, we found the same numbers for both androgen- and EGF-regulated 
genes. For genes involved in invasion, the numbers were much smaller: only 1.5-3% 
was annotated as involved in cell motility and another 3% was involved in cell 
adhesion. It seems logical that androgen- or EGF-regulation of transcription of these 
particular genes result in an increase in proliferation and invasion, but individual genes 
or groups of genes should be studied in detail in to confirm their involvement. 
As described in Chapter 4, possible crosstalk between androgen- and EGF-signalling 
was also analysed. We found more than 50% overlap between androgen- and EGF-
regulated genes involved in proliferation, and approximately 30% for genes involved in 
invasion, and hypothesised that EGF and androgens use partly the same pathways to 
control growth and for the most part separated pathways to control invasion.  
Since the comparisons between androgen- and EGF-regulated genes described in 
Chapter 4 are performed with data partly generated by others (Segawa et al., 2002), 
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the limited overlap in both data sets is a problem. Of all androgen-regulated genes 
present in the Segawa dataset, only 40% was also present on our cDNA array. The 
problem of limited overlap between datasets was also encountered when the impact of 
the androgen- and EGF-pathways in prostate cancer progression was examined. 
Microarray analysis of patient material was compared with the microarray data on 
androgen- or EGF-treated LNCaP cells. Only 83 genes were represented in the prostate 
cancer dataset (Dhanasekaran et al., 2001) and also regulated by androgens and EGF. 
The number of genes regulated by androgens and EGF and specifically expressed in 
metastatic prostate cancer was only 39, and of these genes only 16 were regulated in 
the same direction. From this last experiment we learned that the number of genes 
was too small to draw any conclusions  
Thus, comparing our data with published data has its limitations. Therefore, we 
generated new data on androgen- and EGF-induced genes in an androgen-dependent 
and an androgen-independent prostate cancer cell line (Chapter 5). Noteworthy, the 
two cell lines were related, the same person performed all the experiments at the 
same time, and gene regulation was analysed in 4 time-points, for each variable 
measured. These experiments and their results are described in Chapter 5 and will be 
discussed below. 
 
6.2.2 Gene regulation in androgen-dependent versus androgen-independent 
prostate cancer cells 
 
Transition from androgen-dependent to androgen-independent proliferation of 
prostate cancer cells is the focal point of this thesis. In Chapter 5, using the androgen-
dependent LNCaP-FGC cell line and its androgen-independent derivate LNCaP-LNO, the 
following questions were raised:  
 What are the differences between androgen-dependent and androgen-
independent cells in gene-expression and hormonal control of gene-regulation?  
 Can expression analysis provide insight in how androgen-independent cells 
proliferate without addition of androgens or EGF? 
First, the expression level of ~17,000 genes in the non-hormone-stimulated 
situation was compared. Of ~1,300 genes the difference in expression between 
androgen-dependent and -independent cells was more then 2-fold. The reliability of 
these results was verified by statistical tests and by confirmation of expression of 
known differentially expressed genes. Functional annotation of these genes was 
determined and many genes involved in cell cycle control were found to be up-
regulated in androgen-independent cells as compared to androgen-dependent cells. 
Furthermore, 20% of differentially expressed genes involved in proliferation were also 
androgen or EGF target genes. These results seem to indicate that androgen-
independent cells have become independent because a portion of androgen- or EGF-
regulated genes is constitutively activated. Upon inhibiting signalling at the level of the 
androgen receptor or the EGF receptor, it was observed that constitutive growth of the 
androgen-independent cells could not be impeded. This means that androgen-
independent growth can be the result of mutations, deletions or amplifications of key 
genes acting downstream from the androgen or EGF receptors, or androgen-
independent growth can be the result of autonomous activation of other signalling 
pathways.  
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Second, androgen- and EGF-regulation of gene expression as well as overlap 
between regulated genes in androgen-dependent and androgen-independent cells was 
evaluated. Crosstalk between androgen- and growth factor signalling pathways is 
hypothesised to be involved in prostate cancer progression (Balk, 2002; Shaffer and 
Scher, 2003). Overlap between androgen- and EGF-induced genes could give insight in 
the extent and nature of this crosstalk. Although, one should bear in mind that 
induction of gene expression is an endpoint of signalling and not necessarily is 
achieved via the same pathways. In androgen-independent cells a larger (75% versus 
47%) overlap was found between androgen- and EGF-regulated genes than in 
androgen-dependent cells. More overlap could translate into less dependence on 
androgens for regulation of cellular processes like proliferation and maintenance. The 
genes that show overlap in androgen-independent cells and not in androgen-
dependent cells are mainly involved in signal transduction and metabolism, indicating 
that for these processes, downstream of the androgen and EGF receptors, signalling is 
clearly intertwined.  
 
6.3 Concluding remarks 
 
In this thesis we aimed to discuss molecular and cellular mechanisms involved in 
androgen-independent prostate cancer growth.  
In Chapters 2 and 3, it was observed that loss of expression of the endocytosis 
related gene REPS2 in prostate cancer cells enhances EGF signalling. Furthermore, 
research by others indicated that loss of REPS2 in prostate cancer results in an 
approximate 6-fold increased risk of relapse of the disease, indicating that REPS2 has 
the potential to become a valuable prognostic tool during advanced disease. It was 
also observed that expression of many other endocytosis related genes is changed in 
advanced prostate cancer. Therefore, altered endocytosis could stimulate growth factor 
signalling and may add to the hormone-independent nature of advanced prostate 
cancer.  
In Chapters 4 and 5, other mechanisms putatively involved in androgen-
independent prostate cancer growth were analysed. It is suggested that androgen-
independent cells can proliferate in the absence of androgenic stimulation because: 
first, many cell cycle genes including a number of androgen- and EGF-regulated genes 
are constitutively activated; second, the overlap between androgen receptor signalling 
and EGF receptor signalling pathways is very high (75%); third, other unknown signal 
transduction pathways have been activated and induce proliferation.  
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Prostate cancer has a high incidence in the western world. Early detection of the 
disease is crucial for successful management, since late stages of the disease cannot 
be cured. Unfortunately, however, conventional detection through rising PSA levels is 
already too late in one-third of the cases. These patients have metastatic disease, 
which can only be treated temporarily by androgen ablation therapy. The main 
problem of metastatic prostate cancer is a transition from initially androgen-dependent 
growth to androgen-independent growth. Androgen-independence of prostate cancer 
cells implies resistance to androgen ablation therapy, eventually leading to death of 
the patient.  
Next to androgens, many other growth and differentiation inducing factors play a 
role during development and homeostasis of the prostate and during progression of 
prostate cancer.  Peptide growth factors like EGF, TGF-α, FGF, IGF, NGF, PDGF, VEGF, 
and TGF-β have all been hypothesized to be involved in prostate cancer growth. The 
proposed mechanism of androgen-independent prostate cancer progression is through 
stimulation of proliferation via these factors as compensation for lack of proliferation 
stimulation through androgens. Furthermore, crosstalk between androgen signalling 
and growth factor signalling seems to play a role in prostate cancer growth. Growth 
factors are reported to activate androgen receptors and androgens to induce growth 
factor and growth factor receptor expression.  
In this thesis we focussed mainly on EGF signalling. First, because REPS2, a protein 
potentially involved in androgen-independent prostate cancer, acts through affecting 
EGF signalling, and second, because gene profiling indicated that EGF and androgen 
signalling seem to intertwine in androgen-independent prostate cancer.  
 
We postulated and addressed the following questions in this thesis: 
 
 Via which mechanisms does loss of expression of the endocytosis protein REPS2 
contribute to an androgen-independent phenotype of prostate cancer cells? 
 Is it possible to identify genes, activated by androgens or EGF, that induce 
proliferation and invasion of prostate cancer cells? 
 Do EGF- and androgen-signalling overlap in prostate cancer cells and if so, to 
what extent? 
 What are the differences between androgen-dependent and androgen-
independent cells in gene-expression and hormonal control of gene-regulation?  
 Can expression analysis provide insight in how androgen-independent cells 
proliferate without addition of androgens or EGF? 
 
In Chapter 1, an overview of prostate (cancer) development, androgen signalling, 
growth factor signalling, and growth factor receptor endocytosis is given, as well as a 
description of the microarray technique and analysis. 
In Chapters 2 and 3 the function of REPS2 was investigated. The endocytotic 
protein REPS2 was found in our laboratory as a protein encoded by a transcript that 
was down-regulated in androgen-independent as compared to androgen-dependent 
prostate cancer cells. Considering the functional domains this protein possesses, we 
tried to identify the function of REPS2 in relation to growth factor endocytosis and EGF 
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signalling during progression of prostate cancer. Therefore, REPS2 was transfected in 
prostate cancer cells. As described in Chapter 2, an increase in apoptosis 
(programmed cell death) was found when the protein was expressed at a high level. 
Furthermore, we measured an inhibition of transcriptional activity of a TRE-luciferase 
reporter, which indicates that REPS2 inhibits EGF-signalling. Since these studies were 
performed with transiently transfected cells, which could lead to artificial results, we 
analysed EGF receptor endocytosis and signalling in a stably transfected cell line with 
inducible REPS2 expression at a physiological level (described in Chapter 3). Using 
this androgen-independent prostate cancer cell line we found inhibition of EGF 
endocytosis by increased REPS2 expression. Additionally, an increased level of REPS2 
were shown to inhibit signalling via the EGF receptor. In conclusion we hypothesise 
that loss of REPS2 in androgen-independent prostate cancer cells contributes to an 
androgen-independent phenotype by loss of control of EGF-endocytosis and therefore 
loss of control of EGF-signal transduction. 
 
EGF signalling and its possible involvement in prostate cancer progression was 
investigated further in Chapters 4 and 5. Here we describe microarray experiments 
performed with the prostate cancer cell line LNCaP. First, we investigated induction of 
proliferation and migration of prostate cancer cells by EGF and androgens. Additional 
effects of EGF and androgens on these cellular processes were found when both 
hormones were administrated together. Using microarray analysis, we tried to identify 
genes that would account for the effects. A comparison was made between EGF-
induced genes and R1881-induced genes in LNCaP cells. The latter study, used for this 
comparison, was performed by Segawa et al., 2002. Little overlap between EGF-
induced and R1881-induced genes was found for invasion-involved genes, but most 
genes involved in proliferation were regulated by both hormones. We concluded that 
EGF and R1881 partly use the same pathways to control proliferation.  
Additionally, we compared these two datasets with data on gene expression in a 
series of prostate cancer samples, provided by Dhanasekaran et al., 2001. We found a 
large portion of R1881-regulated genes (also present in the prostate dataset) to be 
metastasis specific, indicating that in these androgen-independent tumour samples the 
androgen-signalling pathway is still active. For EGF-regulated genes this was less clear. 
A problem we encountered during these analyses was loss of data-points due to 
comparison of different microarray chips. Therefore we performed new microarray 
experiments, with androgen-dependent and androgen-independent LNCaP cells treated 
with EGF or R1881; these experiments and analyses are outlined in Chapter 5.  
We focussed mainly on the differences between androgen-dependent and 
androgen-independent gene expression and regulation. A fairly large group of genes 
was found to be expressed differentially between the androgen-dependent and –
independent cell lines in the non-hormone stimulated situation. Annotation of these 
differentially expressed genes showed that many were involved in cell cycle regulation, 
and some of these genes were found to be EGF- or androgen-target genes.  
Next we analysed the overlap between EGF- and R1881-induced genes. It was 
observed that the overlap between EGF- and androgen-signalling was increased from 
40% in androgen-dependent to 75% in androgen-independent LNCaP cells. 
Furthermore, upon analysing genes which were regulated by EGF or R1881, but 
differentially between androgen-dependent and androgen-independent cells, it was 
shown that in androgen-dependent cells many proliferation involved genes are up-
 Summary 
117 
regulated by EGF or R1881, whereas in androgen-independent cells this is not the 
case. These results were confirmed by proliferation studies with EGF and R1881 in both 
cell lines.  
Finally, we postulate, as a possible answer to the question how androgen-
independent cells grow without additional EGF or androgen, that this may be 
effectuated because 1) proliferation-involved genes are stimulated, 2) proliferation-
stimulating pathways are constitutively active, and 3) EGF-signalling largely overlaps 
with androgen-signalling; all of this reducing the need for androgens as the principal 
regulator of growth. The present findings are discussed in Chapter 6. 
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Prostaatkanker komt veel voor in de westerse wereld. Detectie in een vroeg 
stadium is cruciaal voor een succesvolle behandeling, omdat vergevorderde stadia 
ongeneeslijk zijn. Helaas is detectie door middel van stijgende PSA-waarden (prostaat 
specifiek antigeen) in éénderde van de gevallen al te laat. Deze patiënten hebben 
uitgezaaide prostaatkanker, wat alleen tijdelijk behandeld kan worden door androgeen-
depletietherapie. Het belangrijkste probleem bij uitgezaaide prostaatkanker is dat er 
een overgang optreedt van androgeen-afhankelijkheid van de prostaatkanker- cellen 
naar androgeen-onafhankelijkheid. Androgeen-onafhankelijkheid van prostaatkanker-
cellen betekent resistentie tegen androgeen-depletietherapie, wat uiteindelijk de dood 
van de patiënt tot gevolg heeft. 
Naast androgenen spelen vele andere groei- en differentiatie-stimulerende stoffen 
een rol gedurende de ontwikkeling en homeostase van de prostaat en gedurende de 
ontwikkeling van prostaatkanker. Groeifactoren zoals EGF, TGF-α, FGF, IGF, NGF, 
PDGF, VEGF en TGF-β zijn allemaal mogelijk betrokken bij de groei van 
prostaatkanker. Een mogelijk mechanisme voor het ontstaan van androgeen-
onafhankelijke prostaatkanker is stimulatie van groei door deze stoffen in plaats van 
androgenen. Verder is het mogelijk dat samenspraak tussen door groeifactoren 
gestimuleerde signaaltransductie en androgeen-signaaltransductie een rol speelt in 
prostaatkankergroei. Uit publicaties blijkt dat groeifactoren de androgeen-receptoren 
kunnen activeren, en dat androgenen de expressie van groeifactoren en van 
groeifactor-receptoren kunnen stimuleren. 
In het onderzoek beschreven in dit proefschrift hebben we ons voornamelijk bezig 
gehouden met de EGF- signaaltransductie. Ten eerste, omdat REPS2, een eiwit dat 
mogelijk betrokken is bij androgeen-onafhankelijke prostaatkanker, EGF-
signaaltransductie beïnvloedt, en ten tweede omdat uit genen-expressie profielen 
bleek dat EGF-signaaltransductie verweven lijkt te worden met aspecten van 
androgeen-signaaltransductie in androgeen-onafhankelijke prostaatkanker. 
 
Op basis van het voorgaande komen in dit proefschrift de volgende vragen aan de 
orde: 
 
 Door welk mechanisme kan afname van REPS2-expressie bijdragen aan het 
androgeen-onafhankelijke fenotype van prostaatkanker-cellen? 
 Is het mogelijk om door EGF of androgenen geactiveerde genen te identificeren 
die groei en invasie van prostaatkanker-cellen stimuleren? 
 Overlappen EGF- en androgeen-signaaltransductie in prostaatkanker-cellen en zo 
ja, in hoeverre? 
 Zijn genexpressie en genregulatie anders in androgeen-afhankelijke dan in 
androgeen-onafhankelijke cellen? 
 Kan de analyse van expressiepatronen inzicht geven in hoe androgeen-
onafhankelijke cellen kunnen groeien zonder toevoeging van  EGF en androgenen? 
 
In Hoofdstuk 1 is naast een overzicht van prostaat(kanker)-ontwikkeling, 
androgeen-signaaltransductie, groeifactor-signaaltransductie, en groeifactor-receptor 
endocytose, een beschrijving gegeven van de microarray-techniek en -analyse. 
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De Hoofdstukken 2 en 3 beschrijven het onderzoek naar de functie van REPS2. 
Het endocytose-eiwit REPS2 is gevonden in ons laboratorium op basis van een 
transcript dat lager tot expressie komt in androgeen-onafhankelijke cellen vergeleken 
met androgeen-afhankelijke cellen. Gelet op de functionele domeinen die dit eiwit 
heeft, hebben we geprobeerd de functie van REPS2 te achterhalen in relatie tot 
groeifactor-endocytose en EGF-signaaltransductie gedurende de progressie van 
prostaatkanker. REPS2 werd daarom artificieel tot expressie gebracht in 
prostaatkanker-cellen door transiënte transfectie. Zoals beschreven in Hoofdstuk 2, 
werd een toename in apoptose (geprogrammeerde cel-dood) gevonden als het eiwit in 
hoge concentraties tot expressie werd gebracht. Verder werd een remmend effect 
gevonden op de transcriptionele activiteit van een TRE-reporter, wat aangeeft dat 
REPS2 de EGF-signaaltransductie remt. Omdat deze studies uitgevoerd werden met 
transiënte getransfecteerde cellen, wat mogelijk tot artificiële resultaten kan leiden, 
analyseerden we EGF-receptorendocytose en signaaltransductie met een stabiele 
getransfecteerde cellijn met induceerbare REPS2–expressie in fysiologische 
concentratie (beschreven in Hoofdstuk 3). Gebruik makend van deze androgeen-
onafhankelijke prostaatkanker cellijn vonden we een remming van EGF-endocytose 
door een verhoogde REPS2-expressie. Bovendien werd aangetoond dat verhoogde 
concentratie van REPS2, via de EGF-receptor, signaaltransductie remt. De resultaten 
leiden tot de hypothese dat afname van REPS2-expressie in androgeen-onafhankelijke 
prostaatkanker-cellen bijdraagt aan de ontwikkeling van een androgeen-onafhankelijk 
fenotype door verlies van controle op EGF-endocytose en daardoor op EGF-
signaaltransductie. 
 
Het onderzoek naar EGF-signaaltransductie en de mogelijke betrokkenheid ervan in 
prostaatkanker progressie wordt verder uiteengezet in de Hoofdstukken 4 en 5. 
Hierin staan de microarray-experimenten beschreven die uitgevoerd zijn met de 
prostaatkanker-cellijn LNCaP. Ten eerste is in prostaatkanker-cellen de inductie van 
groei en invasie door EGF en androgenen onderzocht. Als beide hormonen tegelijkertijd 
werden toegevoegd, worden additionele effecten van EGF en androgenen gevonden op 
deze cellulaire processen. Met behulp van microarray-analyse werd geprobeerd om 
genen te vinden die deze effecten kunnen veroorzaken. Genen die worden geïnduceerd 
in LNCaP cellen door EGF en androgenen werden met elkaar vergeleken. Voor de 
androgeen-geïnduceerde genen werd een studie gebruikt die was uitgevoerd door 
Segawa et al. (2002). Er werd weinig overlap gevonden tussen EGF-geïnduceerde en 
androgeen-geïnduceerde genen die betrokken zijn bij invasie, maar voor genen die 
betrokken zijn bij proliferatie is de overlap groot. We concludeerden daaruit dat EGF en 
androgenen gedeeltelijk dezelfde signaaltransductie-routes gebruiken om proliferatie 
te stimuleren. 
Daarnaast zijn deze twee datasets vergeleken met genexpressie data van een serie 
prostaatkanker-monsters, geplubiceerd door Dhanasekaran et al. (2001). Een groot 
deel van de androgeen-gereguleerde genen (die ook voorkwamen in de prostaat-
dataset) was metastase-specifiek, wat suggereert dat in deze androgeen-
onafhankelijke tumormonsters de androgeen-signaaltransductieroute nog wel actief is. 
Deze correlatie is minder duidelijk voor EGF-gereguleerde genen. Tijdens deze 
analyses stuitten we op het probleem, dat in de vergelijking van verschillende 
microarray experimenten data verloren gaat omdat verschillende microarray-chips zijn 
gebruikt. Daarom hebben we nieuwe microarray-experimenten uitgevoerd met 
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androgeen-afhankelijke en androgeen-onafhankelijke prostaatkanker-cellen, behandeld 
met EGF of androgenen. Deze experimenten en analyses staan beschreven in 
Hoofdstuk 5. 
In dat hoofdstuk focussen we voornamelijk op de verschillen tussen androgeen-
afhankelijke en androgeen-onafhankelijke genregulatie en genexpressie. Een redelijk 
grote groep genen komt anders tot expressie in androgeen-afhankelijke dan in 
androgeen-onafhankelijke prostaatkanker cellijnen in ongestimuleerde 
omstandigheden. Veel van deze genen zijn betrokken bij regulatie van de celcyclus en 
een aantal hiervan blijkt EGF- of androgeen-targetgen te zijn. 
Vervolgens werd de overlap tussen EGF- of androgeen-gereguleerde genen 
geanalyseerd. De overlap tussen EGF- en androgeen-signaaltransductie blijkt te zijn 
toegenomen van 40% in androgeen-afhankelijke naar 75% in androgeen-
onafhankelijke prostaatkanker-cellen. Verder blijkt dat veel genen betrokken bij 
proliferatie opgereguleerd worden door EGF en androgenen in androgeen-afhankelijke, 
maar niet in androgeen-onafhankelijke cellen. Proliferatie-studies met EGF en 
androgenen in beide cellijnen bevestigden deze resultaten.  
Tenslotte komen we tot het volgende mogelijke antwoord op de vraag hoe 
androgeen-onafhankelijke cellen kunnen groeien zonder extra toegevoegde EGF of 
androgenen: de noodzaak voor aanwezigheid van androgenen als voornaamste groei-
stimulatoren wordt gereduceerd, omdat  
1) genen betrokken bij proliferatie al geactiveerd zijn 
2) signaaltransductie-routes constitutief geactiveerd zijn 
3) EGF-signaaltransductie voor een groot deel overlapt met androgeen-
signaaltransductie.  
Alle resultaten worden bediscussieerd in Hoofdstuk 6. 
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De afgelopen 5 (!) jaar zaten vol ups en downs. Mede door mijn geweldige collega’s, 
vrienden en familie heb ik mijn promotie tot een goed einde gebracht. Ik wil graag van 
de gelegenheid gebruik maken om een paar hier speciaal in het zonnetje te zetten. 
 
Ten eerste mijn promotor en copromotor Anton Grootegoed en Leen Blok.  
Anton, hartelijk bedankt voor het kritisch doorlezen van al mijn schrijfwerk door de 
jaren heen, zonder jouw commentaar was de inhoud van dit proefschrift veel minder 
leesbaar geworden. 
Leen, je was en bent geweldig! Een betere begeleider kan een AIO zich niet wensen. Je 
enthousiasme, peptalks, lees-, correctie- en denkwerk waren onmisbaar. De 
mogelijkheid om op elk moment van de dag binnen te komen walsen met een al dan 
niet blijde boodschap vond ik erg bijzonder. En niet te vergeten je beroemde RNA 
isolaties, al blijven we twisten over de handigheid van je methode, het levert de 
mooiste resultaten op. Dank je wel! 
 
De leden van leescommissie: Prof.dr. Jan Trapman, Dr. Ruud Delwel en Dr. Paul van 
Bergen en Henegouwen, bedankt voor het kritische commentaar op dit proefschrift. 
Paul, jouw wil ik speciaal nog bedanken voor je praktische hulp bij het endocytose-
onderzoek. 
 
Dan natuurlijk mijn collega’s van (tegenwoordig) V&O heel erg bedankt voor alle 
gezelligheid tijdens lunches, koffiepauzes, taarteetfestijnen, borrels en (in een grijs 
verleden) peukpauzes. En niet te vergeten de “oude” 5e het voorgaande geldt ook voor 
julllie! Voor mij blijft het vroegere E&V toch altijd een beetje mijn echte werkplek. Met 
een stel van jullie heb ik na het werk vaak genoten van etentjes, film etc. Leve de 
VPRO-dag! En dan natuurlijk het meidenclubje: Mila, Arzu, Eline, Evelyne, Susanne, 
Liesbeth, Jenny en Marja (in willekeurige volgorde en hopelijk zonder iemand te 
vergeten), de bijzonder gezellige eetavondjes waren altijd weer een succes en een 
heerlijke gelegenheid om lekker te kankeren en te relativeren. Als dames waren we 
zowiezo superieur, toch Susanne en Eline? Hoezee voor “onze” kamer! 
Maar ook door praktische tips en hulp in en rond het lab hebben ik veel aan jullie 
gehad, bedankt. In dit kader wil ik graag speciaal Liesbeth bedanken voor haar hulp bij 
het het vaak moeizame REPS2-onderzoek, heel erg veel dank! 
 
De mensen van het JNI die deelnamen aan het prostaatcluster, bedankt voor de 
nuttige discussies en besprekingen, het was prettig om zo nu en dan vanuit andere 
invalshoeken het prostaatkankerprobleem te bekijken. Met name wil ik Guido noemen, 
bedankt voor je enthousiaste bijdrages. 
Ook wil ik graag Piet van Vliet noemen, je hebt als student hard gewerkt aan het 
REPS2-verhaal, ondanks dat je resultaten niet in het proefschrift terecht zijn gekomen, 
bedankt voor je inzet. 
 
Een speciaal plekje voor Marieke. Als huisgenoot, nee eerder al, als studiegenoot en 
down-under, stonden onze neuzen dezelfde kant op. Dankzij jou ben ik überhaupt aan 
dit avontuur begonnen en ook dankzij jou ben ik er tot het eind mee doorgegaan, wat 
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jij kan kan ik ook! Sinds afgelopen jaar zitten we wat verder van elkaar af, maar 
ondanks dat blijf je belangrijk voor me. Bedankt voor je support en je handige lijstje. 
 
Mijn paranimfen Anne en Anneke, heel erg bedankt dat jullie die speciale rol willen 
vervullen. Ik vind het super dat er zulke geweldige Wageningse meiden in Rotterdam 
wonen! Laten we blijven borrelen, dansen en ouwehoeren tot we bejaard zijn! 
 
Lieve vrienden en vriendinnen, heel erg bedankt dat jullie er zijn en waren om me 
steeds weer op tijd te herinneren aan wat echt belangrijk is in het leven. Bier en 
feestjes! (geintje).  
 
En dan mijn familie voor jullie talent om me al dan niet op vriendelijke wijze te 
stimuleren door te gaan en niet op de laatste plaats voor jullie gebeden, dank jullie 
wel. Ik hoop dat jullie een beetje trots op me zijn. 
Mijn tweede familie (sinds 19 mei 2004), dank jullie wel voor de interesse in mijn 
onderzoek al was het misschien niet altijd even makkelijk te volgen of interessant. 
 
Lief, heel veel dank voor je eeuwig nodige steun, je gebed en je vertrouwen in mij. 
Ook je wil om te begrijpen waar ik mee bezig was en je hulp met het maken van een 
goed draaiende cd-rom waren onmisbaar. 
 
Michiel, ik kan niet zonder jou 
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ACK2 Activated CDC42-
associated tyrosine 
kinase 2 
AP-2 Adaptor-related protein 
complex 2 
AR   Androgen receptor  
BSA  Bovine serum albumin 
CALM   Calmodulin 1 
CBL Cas-Br-M (murine) 
ecotropic retroviral 
transforming sequence  
CDC2  Cell division cycle 2 
CDC42  Cell division cycle 42  
CWR22  Case Western Reserve22 
DCC Dextran-coated charcoal 
treated 
DNA  Deoxyribonucleic acid 
e.g.  For example (exempli 
gratia) 
EGF  Epidermal growth factor  
EGR-1  Early growth response 1 
EH   EPS homology 
EPN1  Epsin 1 
EPS Epidermal growth factor 
receptor pathway 
substrate  
ERK extracellular (signal-) 
regulated kinase  
FCS  Foetal calf serum 
FGC  Fast growing colony 
FGF  Fibroblast growth factor 
FOS v-Fos FBJ murine 
steosarcoma viral 
oncogene homolog 
GAP GTPase-activating protein 
GEF  Guanine exchange factor 
GFP  Green fluorescent protein 
GRB2 Growth factor receptor-
bound protein 2  
GTP  Guanine triphosphate  
HGF/SF Hepatocyte growth 
factor/scatter factor 
HGS Hepatocyte growth 
factor-regulated tyrosine 
kinase substrate 
IGF  Insulin-like growth factor 
 
 
 
IGFBP2 Insulin-like growth factor 
binding protein 2 
JUN v-Jun sarcoma virus 17 
oncogene homolog  
kDa  Kilo Dalton 
LNCaP Lymph node carcinoma of 
human prostate 
LNO Lymph node original 
MAPK Mitogen-activated protein 
kinase  
PAGE Polyacrylamide gel 
electrophoresis 
PBS Phosphate-buffered 
saline 
PC3  Prostatic carcinoma 3 
PI3Kinase Phosphoinositide-3-
kinase 
POB1  Partner of RALBP1 
PSA  Prostate specific antigen  
PTEN Phosphatase and tensin 
homolog 
RAC1 Ras-related C3 botulinum 
toxin substrate 1 
RALA v-Ral simian leukemia 
viral oncogene homolog A 
(Ras related) 
RALBP1  RALA binding protein 1 
REPS2 RALBP1 associated EPS 
domain containing 2  
RNA  Ribonucleic acid 
RPMI 1640 Roswell Park Memorial 
Institute 1640 
RXR  Retinoid X receptor 
SD   Standard deviation 
SDS  Sodium dodecyl sulphate 
SH3  SRC homology 3 
SHC SRC homology 2 domain 
containing 
TGF-α  Transforming growth 
factor-α  
TMEFF2  Transmembrane protein 
with EGF-like and two 
follistatin-like domains  
TRE  TPA responsive element 
TRPS1 Trichorhinophalangeal 
syndrome I 
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Inleiding 
 
Prostaatkanker komt veel voor in de westerse wereld. Het is cruciaal voor 
een succesvolle behandeling dat de kanker in een vroeg stadium wordt 
gedetecteerd, omdat vergevorderde prostaatkanker ongeneeselijk is. Helaas 
wordt bij éénderde van de gevallen de ziekte te laat ontdekt en is er sprake 
van uitgezaaide prostaatkanker. Deze patiënten worden dan, naast dat hun 
prostaat verwijderd wordt, behandeld met een zogenaamde androgeen-
depletietherapie. Deze therapie is erop gebaseerd dat de prostaatcellen en 
ook prostaatkanker-cellen androgenen (mannelijke hormonen, zoals 
testosteron) nodig hebben om te overleven. Als de androgenen dus 
kunstmatig laag worden gehouden door androgeen-depletietherapie gaan die 
cellen dood. Helaas kunnen prostaatkanker-cellen na een bepaalde periode 
zonder androgenen ook overleven en worden ze resistent tegen de 
androgeen-depletietherapie, wat uiteindelijk de dood van de patiënt tot 
gevolg heeft. Deze omslag van androgeen-afhankelijkheid naar androgeen-
onafhankelijkheid is het hoofdonderwerp van mijn onderzoek. 
Naast androgenen zijn er ook nog vele andere stoffen die een rol spelen 
tijdens het normale functioneren van de prostaat en het ontstaan van 
prostaatkanker. Een groep van deze stoffen zijn de groeifactoren. Van deze 
stoffen wordt verondersteld dat ze de groei van androgeen-onafhankelijke 
prostaatkankercellen stimuleren als vervanging van de androgenen. Het zou 
ook kunnen dat deze stoffen niet als vervanging van androgenen gaan 
werken, maar meer gaan samenwerken met androgenen om zo het tekort 
aan androgenen te compenseren.  
In dit proefschrift wordt voornamelijk het onderzoek beschreven naar de 
invloed van EGF (epidermale groeifactor) op de progressie van 
prostaatkanker. Ten eerste omdat REPS2, een eiwit wat mogelijk betrokken 
is bij androgeen-onafhankelijke prostaatkanker, invloed heeft op de EGF-
werking. Ten tweede omdat uit experimenten bleek dat androgenen en EGF 
meer lijken te gaan samenwerken in androgeen-onafhankelijke 
prostaatkanker, vergeleken met androgeen-afhankelijke prostaatkanker. 
 
Het onderzoek 
 
Op basis van het voorgaande werd aan de hand van de volgende vragen het 
onderzoek opgebouwd: 
 
1. Door welk mechanisme kan afname van REPS2-expressie1 bijdragen aan 
de androgeen-onafhankelijkheid van prostaatkankercellen? 
2. Is het mogelijk om genen te identificeren die door EGF of androgenen 
groei en invasie2 van prostaatkankercellen stimuleren? 
3. Werken EGF en androgenen samen en zo ja, in hoeverre? 
4. Verschillen androgeen-afhankeljke en androgeen-onafhankelijke cellen 
van elkaar op genetisch niveau? 
5. Kan de analyse van gen-expressiepatronen inzicht geven in hoe 
androgeen-onafhankelijke cellen kunnen groeien zonder EGF en 
androgenen?  
 
 
In Hoofdstuk 1 is een overzicht gegeven van de prostaat(kanker)-
ontwikkeling, het werkingsmechanisme van androgenen en groeifactoren en 
een beschrijving van de microarray-techniek en –analyse. Deze techniek 
wordt vooral gebruikt voor het onderzoek beschreven in de hoofstukken 4 en 
5. Simpel gezegd is het doel ervan om in één experiment het totale 
expressiepatroon, dus de activiteit van alle genen, van bijvoorbeeld 
androgeen-afhankelijke cellen te bepalen. 
De Hoofdstukken 2 en 3 beschrijven het onderzoek naar de functie van 
REPS2. In ons laboratorium is het eiwit REPS2 gevonden als een eiwit dat 
lager tot expressie komt in androgeen-onafhankelijke cellen vergeleken met 
androgeen-afhankelijke cellen. Gelet op de functionele domeinen die dit eiwit 
heeft, hebben we geprobeerd de functie van REPS2 te achterhalen in relatie 
tot groeifactor-internalisatie3 en het werkingsmechanisme van EGF 
gedurende de progressie van prostaatkanker. Met behulp van moleculaire 
technieken werd REPS2 artificieel tot expressie gebracht in prostaatkanker-
cellen. Zoals beschreven in Hoofdstuk 2 werd een toename in apoptose 
(geprogrameerde cel-dood) gevonden in cellen die veel REPS2 tot expressie 
brachten. Verder werd een remmend effect gevonden op het EGF 
werkingsmechanisme. Omdat de technieken die we voor deze experimenten 
gebruikten tot artificiële resultaten kunnen leiden hebben we vervolgens 
cellen gemaakt waarin we REPS2 gecontroleerd tot expressie kunnen 
brengen (beschreven in Hoofdstuk 3). Met behulp van deze cellen konden 
we een remming van EGF-internalisatie aantonen als we de concentratie van 
REP2 verhoogden. Bovendien werd weer een remmend effect gevonden op 
het EGF werkingsmechanisme. De resultaten leiden tot de hypothese dat 
afname van REPS2-expressie tijdens de ontwikkeling van androgeen-
onafhankelijke prostaatkanker bijdraagt aan het androgeen-onafhankelijke 
karakter, door verlies van controle op EGF-internalisatie en daardoor op het 
EGF werkingsmechanisme. 
 
Het onderzoek naar het EGF werkingsmechanisme en de mogelijke 
betrokkenheid ervan in prostaatkanker-progressie wordt verder uiteengezet 
in de Hoofdstukken 4 en 5. Hierin staan de microarray-experimenten 
beschreven die uitgevoerd zijn met de prostaatkankercellen. Ten eerste is de 
stimulatie van groei en invasie door androgenen en EGF onderzocht. Met 
behulp van microarray-analyse werd geprobeerd om genen te vinden die 
deze effecten kunnen veroorzaken. Genen die worden geactiveerd door EGF 
of door androgenen werden met elkaar vergeleken. Voor de androgeen-
geactiveerde genen werd een studie uitgevoerd door Segawa et al., 2002 
gebruikt. Er werd niet veel samenwerking gevonden tussen EGF en 
androgenen wat betreft stimulatie van invasie, maar voor groei werd wel veel 
samenwerking gevonden. 
Daarnaast hebben we de EGF en de androgeen dataset vergeleken met 
genexpressie data van een serie prostaatkanker-monsters, gepubliceerd 
door Dhanasekaran et al., 2001. Een groot deel van de androgeen-
gereguleerde genen (die ook voorkwamen in de prostaatkankerset) was 
specifiek voor monsters van uitgezaaide tumoren, wat suggereert dat in deze 
androgeen-onafhankelijke tumoren het androgeen werkingsmechanisme nog 
wel actief is. Deze correlatie is minder duidelijk voor EGF-gereguleerde 
genen. Tijdens deze analyses stuiten we op het probleem dat door 
verschillende microarray-experimenten met elkaar te vergelijken data 
verloren gaat omdat er verschillende microarrays zijn gebruikt met 
verschillende genen erop. Daarom hebben we nieuwe microarray-
experimenten uitgevoerd met zowel androgeen-afhankelijke als androgeen-
onafhankelijke cellen, behandeld met EGF of androgenen. Deze experimenten 
en analyses zijn beschreven in Hoofdstuk 5. 
In dat hoofdstuk focussen we voornamelijk op de verschillen tussen 
androgeen-afhankelijke en androgeen-onafhankelijke genregulatie en 
genexpressie. Een redelijk grote groep genen komt anders tot expressie in 
androgeen-afhankelijke dan in androgeen-onafhankelijke prostaatkanker 
cellijnen in ongestimuleerde omstandigheden. Veel van deze genen zijn 
betrokken bij regulatie van de celcyclus en een aantal hiervan blijkt EGF- of 
androgeen-targetgen te zijn. 
Vervolgens werd de overlap tussen EGF- of androgeen-gereguleerde genen 
geanalyseerd. De overlap tussen EGF- en androgeen-signaaltransductie blijkt 
te zijn toegenomen van 40% in androgeen-afhankelijke naar 75% in 
androgeen-onafhankelijke prostaatkanker-cellen. Verder blijky dat veel 
genen betrokken bij proliferatie opgereguleerd worden door EGF en 
androgenen in androgeen-afhankelijke, maar niet in androgeen-
onafhankelijke cellen. Proliferatie-studies met EGF en androgenen in beide 
cellijnen bevestigden deze resultaten.  
Tenslotte komen we tot het volgende mogelijke antwoord op de vraag hoe 
androgeen-onafhankelijke cellen kunnen groeien zonder extra toegevoegde 
EGF of androgenen: de noodzaak voor aanwezigheid van androgenen als 
voornaamste groei-stimulatoren wordt gereduceerd, omdat 1) genen 
betrokken bij proliferatie al gestimuleerd worden, 2) signaaltransductie-
routes constitutief geactiveerd zijn en 3) omdat EGF-signaaltransductie voor 
een groot deel overlapt met androgeen-signaaltransductie. Alle resultaten 
worden bediscussieerd in Hoofdstuk 6. 
 
Voetnoten 
1 Gen-expressie houdt in dat een gen (een stukje DNA dat informatie bevat 
voor de vorming van een specifiek eiwit) geactiveerd wordt, en dat het 
bewuste eiwit gemaakt wordt. 
2 Invasie betekend dat een cel zijn oorspronkelijke positie verlaat en zich 
beweegt naar een andere plaats en zich daar vastzet. 
3 Groeifactor-internalisatie is het proces waarbij door vervormingen van de 
celwand groeifactoren van buiten de cel naar binnen de cel worden 
getransporteerd.  
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